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Abstract: The worldwide outbreak of COVID-19 was caused by a pathogenic virus called Severe
Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Therapies against SARS-CoV-2 target the
virus or human cells or the immune system. However, therapies based on specific antibodies, such
as vaccines and monoclonal antibodies, may become inefficient enough when the virus changes its
antigenicity due to mutations. Polyphenols are the major class of bioactive compounds in nature,
exerting diverse health effects based on their direct antioxidant activity and their effects in the modu-
lation of intracellular signaling. There are currently numerous clinical trials investigating the effects
of polyphenols in prophylaxis and the treatment of COVID-19, from symptomatic, via moderate and
severe COVID-19 treatment, to anti-fibrotic treatment in discharged COVID-19 patients. Antiviral
activities of polyphenols and their impact on immune system modulation could serve as a solid basis
for developing polyphenol-based natural approaches for preventing and treating COVID-19.
Keywords: SARS-CoV-2; polyphenols; antiviral effects; antiviral targets
1. Introduction
The worldwide outbreak of COVID-19 was caused by a pathogenic virus called
Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), belonging to the β-
coronaviruses lineage B. At the beginning of the pandemic, respiratory symptoms led to
the assumption that COVID-19 exclusively affects the respiratory system, but later on,
growing evidence demonstrated also SARS-CoV-2-mediated extra-respiratory manifes-
tations and complications, such as cardiac, gastrointestinal, hepatic, renal, neurological,
olfactory, ocular, cutaneous, hematological, and reproductive [1–3], clearly demonstrating
that COVID-19 is a multisystem disease. The virus uses a surface glycoprotein, called a
‘spike’ protein (S protein), to bind to angiotensin-converting enzyme 2 (ACE2) and enter
the host cell. ACE2 has a role in the regulation of vasoconstriction and blood pressure,
and although it is most abundant on type II alveolar cells, several studies have shown that
ACE2 is expressed not only in lung tissues but also in extra-pulmonary organs such as
the heart, kidney, liver, colon, esophagus, brain, gallbladder and testis, explaining why
SARS-CoV-2 may also affect extra-pulmonary organs [4].
Therapies against SARS-CoV-2 target the virus or human cells or the immune system.
The key SARS-CoV-2 targets comprise three non-structural proteins (3CLpro, PLpro, and
RdRp) and a structural protein (S protein), which are responsible for replication, tran-
scription, and host cell recognition [5]. However, on the one hand, therapies based on
Int. J. Mol. Sci. 2021, 22, 12385. https://doi.org/10.3390/ijms222212385 https://www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2021, 22, 12385 2 of 29
specific antibodies, such as vaccines and monoclonal antibodies, may become inefficient
enough when the virus changes its antigenicity due to mutations. On the other hand,
many serious adverse effects have been reported during the application of pharmacological
treatments [6]. Therefore, novel strategies with improved efficiency and safety are still
needed. As nature offers a tremendous treasury of different chemical compounds with
anti-viral and health-promoting activity at the same time, an increasing number of studies
are dedicated to uncovering the potential of natural products, such as polyphenols, to
combat COVID-19 [7–11].
Polyphenols are the major class of bioactive compounds in nature, exerting diverse
health effects based on their direct antioxidant activity and their effects in the modulation
of intracellular signaling [12,13]. Antiviral activities of polyphenols and their impact on
immune system modulation could serve as a solid basis for developing polyphenol-based
natural approaches for preventing and treating COVID-19 [14]. Besides antiviral activities
and immune system regulation, the pleiotropic and multi-organ health-promoting effects
of polyphenols [15,16] make them even more beneficial to combat COVID-19, taking
into account the multisystem complications of this disease. In addition, polyphenols are
natural food components and thus safe even at high daily doses (gram quantities) [17],
available from sustainable resources, inexpensive, and easy to isolate/purify, even from
food industry waste.
Therefore, this review aims to present molecular mechanisms of possible action of
polyphenols in protection and prevention against COVID-19, based on literature data
obtained from in vitro, in vivo, and clinical studies, as well as to review the potential of
polyphenol structures as inspiration for drugs under development to be used for COVID-
19 prevention and treatment. Literature data for this review was collected using the
Scopus database in the period from 2019 to 2021. Keywords used for the search were
polyphenols, COVID-19, SARS-CoV-2, Spike protein, 3CLpro, Mpro, and PLpro. Due to the
high similarity between SARS-CoV and SARS-CoV-2 key protein targets, some in vitro
effects of polyphenols previously reported for SARS-CoV are also presented.
2. Health Effects of Polyphenols Related to COVID-19
Polyphenols, the major class of bioactive compounds in nature, are plant secondary
metabolites comprising compounds of diverse structures, molecular weights, and prop-
erties and are ubiquitously present in plant-based foods. According to the polyphenol
definition of Quideau et al. [18], the term “polyphenol” should be used to define plant
secondary metabolites derived exclusively from the shikimate-derived phenylpropanoid
and/or the polyketide pathway(s), featuring more than one phenolic ring and being devoid
of any nitrogen-based functional group in their most basic structural expression. Although
all monophenolic structures, such as phenolic acids, and the naturally occurring derivatives,
such as methyl phenyl ethers and O-phenyl glycosides, are excluded from this definition,
due to their various biological activities resembling those of polyphenols, these compounds
are studied in parallel with true polyphenols for their sanative health effects. The structures
of some phenolic acids and polyphenol classes are presented on Figure 1.
A structural feature common to all plant phenolic compounds is the presence of an
aromatic ring and at least one hydroxyl group. Compounds with more than one phenolic
ring are known as polyphenol compounds. Therefore, to be precise, phenolic acids, with
their structures of the C6-C1 (benzoic acid derivatives) or C6C3 (cinnamic acid derivatives)
types, are not polyphenols. The most common dietary phenolic acids are caffeic acid, gallic
acid, ferulic acid, chlorogenic acid, and p-coumaric acid [19].
Flavonoids are polyphenols with the C6-C3-C6 general backbone structure, where
the two C6 units (Ring A and Ring B) of a phenolic nature are bridged by chromane
ring (Ring C), and according to the hydroxylation pattern and variations in the chromane
ring flavonoids are divided into flavans, flavanones, isoflavanones, flavones, isoflavones,
anthocyanidins, chalcones, and flavonolignans [20].
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Figure 1. Structures of some phenolic acids and several classes of polyphenols. p-Coumaric acid (A), caffeic acid (B), gallic 
acid (C), flavan (D), flavone (E), isoflavone (F), chalcone (G), anthocyanidin (H), condensed tannin (I), gallotannin (J), 
ellagitannin (K), fucol (L), phloroethol (M), fucophloroethol (N), eckol (O), fuhalol (P), and carmalol (Q). 
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their structures of the C6-C1 (benzoic acid derivatives) or C6C3 (cinnamic acid deriva-
tives) types, are not polyphenols. The most common dietary phenolic acids are caffeic 
acid, gallic acid, ferulic acid, chlorogenic acid, and p-coumaric acid [19]. 
Flavonoids are polyphenols with the C6-C3-C6 general backbone structure, where 
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Figure 1. Struct res of some phenolic acids and several classes f l l . p-Coumaric acid (A), caffeic acid (B), gallic
acid (C), flavan (D), flavone (E), isoflavone (F), chalcone (G), anthocyanidin (H), condensed tannin (I), gallotannin (J),
ellagitannin (K), fucol (L), phloroethol (M), fucophloroethol (N), eckol (O), fuhalol (P), and carmalol (Q).
Some polyphenols may undergo oligomerization to form higher mol cular weight
compounds, commonly known as “true” vegetable ta nins. The conde sed tannins are
also known as proanthocya idins, such as procyanidins, prod lphinidi s, and profisetini-
dins, which are formed by the oligomerization of flavan-3-ol units such as (epi)catechin,
epigallocatechin, and fisetinidol. Hydrolyzable tannins include the gallo- and ellagitannins
(hydrolyzable tannins), which are derived from the metabolism of the shikimate-derived
gallic acid that leads through esterification and phenolic oxidative coupling reactions to
numerous (close to 1000) monomeric and oligomeric polyphenolic galloyl ester derivatives
of sugar-type polyols, mainly D-glucose [18]. The phlorotannins are synthesized by red-
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brown algae and are structurally analogous to tannins from terrestrial plants. They are
comprised of polymeric chains of base phloroglucinol (1,3,5-trihydroxybenzene) residues
connected via C-C and/or C-O-C couplings and are classified as fucols (phenyl bond),
phloroethols (ether bond), fucophloroethols (ether and phenyl bonds), eckols, fuhalols, and
carmalols [21].
The effects of polyphenols on human health are based on phenolic–protein interactions,
covalent and/or noncovalent (hydrophobic interactions, hydrogen bonding, van der Waals
interactions, electrostatic interactions, steric repulsive forces, ion bridging, and dipole–
dipole/charge–dipole interactions). At the molecular level, by interactions of polyphenols
and their metabolites with functional proteins, such as intracellular enzymes, transcription
factors (TFs), receptors and other functional proteins, via a multiple-target mechanism and
in a complex interaction manner, polyphenols modulate regulation of cell events, signaling
pathways, and metabolic processes [22].
The health benefits of polyphenols have been the focus of thousands of studies pub-
lished in the last few decades. With their antiviral, antioxidant, anti-inflammatory and
multi-organ protective effects, polyphenols are promising potent weapons to mitigate
the major pathways involved in the pathogenesis of SARS-CoV-2, as well as to improve
recovery of impaired multi-organ systems in post-COVID-19 patients.
Several recent reviews recognized and presented different aspects of potential use of
polyphenols against COVID-19 by assessing the effects of polyphenols on COVID-19 drug
targets [5]; the underlying mechanism of polyphenols antiviral and immune-regulation
activities in COVID-19 [23]; the possibility to use polyphenols for the development of
novel natural approaches against COVID-19 [6,24]; polyphenols potential in strengthening
antioxidant defenses and upregulating the immune systems; and in prevention, replication,
and spreading of the SARS-CoV-2 [25]. Similarly, the role of key medicinal/nutritional
antioxidants, including polyphenols, in the antiviral immune response in COVID-19 [26],
mechanism of polyphenol action in COVID-19 in comparison to other acute infectious
diseases [27], potential of polyphenols in reducing COVID-19 cytokine storm [28,29],
and potential of polyphenols in tuning of autophagy and ubiquitin-proteasome system
pathways in COVID-19 [30] were reviewed. The use of tea polyphenols in prophylaxis
and treatment of COVID-19 [31,32]; polyphenol potential for modulating the expression
of host microRNAs that play role in SARS-CoV-2 infection [33]; and beneficial effects of
polyphenols against the COVID-19-induced lung damage and associated systemic effects
based on predictive, preventive, and personalized medicine (3PM) were also critically
studied [34].
Although the total polyphenol intake for the general population is estimated to be 0.9 g
per day [35], upon ingestion, only 5–10% of the total polyphenol intake is absorbed in
the small intestine, while the remaining 90–95% may accumulate in the large intestinal
lumen up to the millimolar range [36]. In the gastrointestinal tract (GIT), polyphenols are
subjected to phase I/II metabolism and then carried out in gut and liver cells. In contrast,
unabsorbed polyphenols are degraded by microflora in the colon and thereafter partly
absorbed by the hepatic portal vein. From the liver, polyphenols and their metabolites
enter systemic circulation and are absorbed by peripheral tissues where they exert their
bioactivities [13]. Therefore, despite high daily intake, in peripheral tissues intact polyphe-
nols reach very low concentrations, typically in the nanomolar range, presumably too low
to have a direct impact on the antioxidant capacity [37]. Still, their metabolites, found in
comparably greater amounts, may act as direct radical scavengers and mainly contribute to
exerted bioeffects [13]. Consequently, future studies on the beneficial effects of polyphenols
in COVID-19 should also take into account polyphenol bioavailability, the contribution
of their metabolites in observed bioactivities, and their effective concentrations in target
tissues. It is worth mentioning that appropriate combinations of different phenolics were
shown to enhance the bioactivities of individual compounds, resulting in a positive syner-
gistic/additive effect depending on the amounts of the phenolics [22]. Therefore, future
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studies should focus on testing these proved beneficial combinations of polyphenolics in
the fight against COVID-19.
When administered orally, polyphenols should have unambiguous beneficial effects
in preventing and treating COVID-19, at least in GIT. In fact, SARS-CoV-2 is frequently
found in the stool, and gastrointestinal tissue samples of patients with COVID-19 [38],
and SARS-CoV-2 also infects the GIT via ACE2 receptor highly expressed throughout
the GIT [39]. This suggests that, while the respiratory tract is the primary site for SARS-
CoV-2 infection, the fecal-oral route is an alternative route by which SARS-CoV-2 can
spread [32]. On the other hand, GIT dysfunction in critically ill COVID-19 patients may be
related to critical illness and associated systemic inflammation and treatments, independent
of GIT infection [40]. Therefore, upon polyphenol ingestion, excessive concentrations
(in millimolar range) of polyphenols and their metabolites along GIT could be of great
importance in the fight against COVID-19 in situ, particularly in the cases of SARS-CoV-2
infection of GIT, prevention of fecal-oral transmission, and alleviation of GIT complications
in critically ill patients. It is known that upon ingestion, polyphenols interact with proteins
within the oral cavity, such as proline-rich proteins secreted in the saliva [41] or saliva
mucins [42]. Moreover, since high expression of ACE2 receptor of SARS-CoV-2 was found
on the epithelial cells of the oral mucosa, particularly on epithelial cells of the tongue, the
oral cavity is considered as potential high risk for SARS-CoV-2 infection [43]. Therefore,
upon ingestion, polyphenols could inhibit SARS-CoV-2 entry and its replication, thus
reducing risk for SARS-CoV-2 infection by binding to viral and/or host proteins in the
oral cavity.
There are currently numerous clinical trials (Table 1) investigating the effects of
polyphenols in prophylaxis and the treatment of COVID-19 from symptomatic via moderate
and severe COVID-19 treatment to anti-fibrotic treatment in discharged COVID-19 patients.
In these clinical trials, polyphenols are assessed as pure polyphenols, pure polyphenols in
combination with vitamins/minerals and/or other natural bioactive compounds or drugs,
polyphenol-rich extracts, or polyphenol-rich extracts in combination with other bioactive
components or drugs.
Table 1. Clinical trials investigating the effects of polyphenols in prophylaxis and the treatment
of COVID-19.









Pure polyphenols in combination with vitamins/minerals







Pure polyphenols in combination with drugs NCT04622865NCT04590274
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3. Overview of SARS-CoV-2 and Its Main Antiviral Protein Targets
The virus responsible for the COVID-19 pandemic, SARS-CoV-2, is the seventh coro-
navirus that can infect humans. Like other coronaviruses, it has either a spherical or
pleomorphic structure with a viral particle size of about 150–160 nm [27]. It contains
positive single-stranded RNA. Structural proteins of this virus are envelope protein (E),
nucleocapsid protein (N), membrane glycoprotein (M), and spike glycoprotein (S) [44]. Un-
like other coronaviruses, SARS-CoV-2 has additional glycoprotein with acetylesterase and
hemagglutination activity. SARS-CoV-2 genome organization is typical for coronaviruses,
consisting of 5′ and 3′ untranslated regions, two open reading frames, ORF1a and ORF1b,
and the following genes: S, N, M, and E. Two ORF regions code for 16 nonstructural
proteins (nsp), namely nsp1-16 [45]. Between ORF1a and ORF1b regions is the location of
−1 frameshift, and as a consequence, two polypeptides are coded, pp1a and pp1ab. These
polypeptides are further processed by viral-encoded proteases, thus forming 16 nsp [46].
The overall structure of SARS-CoV-2 is shown in Figure 2.
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Figure 2. Structure of SARS-CoV-2 virus. i re 2. Structure of SARS-CoV-2 virus.
Coronaviruses, including SARS-CoV-2, have a remarkable ability for interspecies
transmission, which is, at least in part, attributed to various strategies they employ to infect
target cells [47]. Spike glycoprotein (S protein), consisting of two subunits named S1 and S2,
is the protein mainly responsible for coronavirus infectivity and host specificity. Similar
to SARS-CoV, cell entry of SARS-CoV-2 is dependent on binding of S1 subunit to cellular
angiotensin-converting enzyme 2 (ACE-2) receptor and S protein priming at S1/S2 and S2′
sites by host cell transmembrane protease, serine 2 (TMPRSS2), and cysteine proteases
cathepsin B and L [48]. Unlike SARS-CoV, cell entry of SARS-CoV-2 is preactivated by
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proprotein convertase furin [49]. Upon cleavage, the S2 subunit mediates fusion of viral
envelope, host cell membrane, and endosome. The activity of S2 and lower pH leads to the
viral genome’s release into the cytoplasm [50]. At this point, the endoplasmic reticulum
is utilized to produce double-membrane vesicles, which protect the viral genome and
enable replication to occur. With the help of the host cell, the viral genome is translated
to polypeptides which are then separated into structural and nonstructural proteins with
the action of two viral proteases, papain-like protease (PLpro) and 3-chymotrypsin-like
protease (3CLpro). As 3CLpro cleaves most polypeptide sites, it is also known as the main
protease or Mpro. Assembly of whole virions takes place in the endoplasmic reticulum and
Golgi apparatus. Virions then leave the host cell by exocytosis and are ready to infect new
cells [51]. Although S protein plays a crucial role in SARS-CoV-2 infectivity, other proteins
are also of great importance for the structural integrity of the virus and its function. For
instance, N protein is essential for the viral structure and its ability to bind viral RNA,
making ribonucleoprotein complex, which is crucial for the replication of the virus. Both E
and M proteins play a role in viral particles assembly, while E protein also serves as an ion
channel [52].
Essential proteins involved in the virus replication cycle are often targets of antiviral
drugs. An overview of major proteins of SARS-CoV-2 acting as antiviral targets will be
given in the following subsection.
3.1. Primary Antiviral Protein Targets of SARS-CoV-2
3.1.1. Spike (S) Protein
When considering SARS-CoV-2 structural proteins, spike or S-protein is getting the
most attention being the one responsible for the attachment of the virus to the host cell. S
protein has a molecular mass of 180–200 kDa in a monomeric state, and it consists of two
domains, S1 and S2. S1 domain, responsible for binding to ACE2 receptor, is composed
of N-terminus domain and receptor-binding domain (RBD). S2 domain, responsible for
viral fusion with the host cell membrane, consists of fusion peptide, heptapeptide repeat
sequence 1 and 2 (HR 1 and 2), transmembrane domain (TM), and cytoplasm domain (CT).
In the native state, S protein is a trimer. Its structure has been determined by cryo-electron
microscopy. It was noted that it could exist in two forms, named closed and opened.
Hinge-like movement of the RBD domain makes these two forms, with opened one being
able to interact with ACE2 receptor [53,54]. The structure of the S protein interacting with
the ACE2 receptor is shown in Figure 3.




Figure 3. Structure of SARS-CoV-2/ACE 2 receptor complex. The upper, wider part is the S1 domain 
that interacts with the ACE2 receptor, colored in green, while the lower, narrower part is the S2 
domain. Blue squares represent carbohydrates. Image obtained by Cong et al., 2021[55], PDB entry: 
7DF4. 
Different strategies are being utilized to find the appropriate way to interrupt the 
proper function of S viral protein, including prevention of its binding to ACE2 receptor, 
inhibition of its fusion function, and inhibition of proteases responsible for its cleavage 
[53]. Antibodies, synthetic peptides, and other molecules, including polyphenols, are be-
ing tested for this application. Considering that RBD domains of SARS-CoV and SARS-
CoV-2 have about 75% homology in amino acid sequence, antibodies and molecules that 
target this domain might not be equally effective for both viruses [56]. 
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3CLpro/Mpro, Figure 4, is a nonstructural protein of coronaviruses in general. This en-
zyme cleaves viral polyproteins, thus creating proteins required for virus replication and 
maturation. Two polypeptides named protomer A and B form a dimeric structure of 
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domains II and III. The location of Cys-His catalytic dyad of 3CLpro and substrate binding 
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Different strategies are being utilized to find the appropriate way to interrupt the
proper function of S viral protein, including prevention of its binding to ACE2 receptor,
inhibition of its fusion function, and inhibition of proteases responsible for its cleavage [53].
Antibodies, synthetic peptides, and other molecules, including polyphenols, are being
tested for this application. Considering that RBD domains of SARS-CoV and SARS-CoV-2
have about 75% homology in amino acid sequence, antibodies and molecules that target
this domain might not be equally effective for both viruses [56].
3.1.2. CLpro/Mpro
3CLpro/Mpro, Figure 4, is a nonstructural protein of coronaviruses in general. This
enzyme cleaves viral polyproteins, thus creating proteins required for virus replication
and maturation. Two polypeptides named protomer A and B form a dimeric structure of
3CLpro. Each protomer is composed of three domains. Domains I and II have antiparallel
β-barrel structure, while domain III has five α-helices. An extended loop region connects
domains II and III. The location of Cys-His catalytic dyad of 3CLpro and substrate binding
site is in a cleft between domains I and II. These structural characteristics are similar to
Mpro enzymes of other coronaviruses [57].
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ideal therapeutic target. Amino acid sequence similarity of 3CLpro from SARS-CoV-2 is 
about 96% compared to the one from SARS-CoV with a difference in only 12 out of 303 
positions in the amino acid sequence. Crystal structures of SARS-CoV and SARS-CoV-2 
main proteases showed that the active sites of these enzymes are conserved [58]. Consid-
ering there is high homology between the two proteases, it is plausible to speculate that 
effective inhibitors discovered for 3CLpro from SARS-CoV would also be effective against 
the same protease from SARS-CoV-2. 
3.1.3. PLpro 
Along with its protease activity, PLpro can modulate the innate immune response by 
cleaving ubiquitin and interferon-stimulated gene 15 (ISG15), known regulators of host 
innate immune pathways. Amino acid sequences of PLpro from SARS-CoV and SARS-
CoV-2 are 83% identical. Interestingly, PLpro from SARS-CoV and SARS-CoV-2 do not 
have the same specificity. The one from SARS-CoV acts more specifically on ubiquitinated 
substrates, and the one from SARS-CoV-2 preferentially acts on ISG15-conjugated sub-
strates. Inhibition of this protease stops viral replication [59]. The structure of PLpro from 
SARS-CoV 2 is presented in Figure 5. 
 
Figure 5. Crystal structure of PLpro protease from SARS-CoV-2. Subdomains are color-coded and 
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Figure 4. Crystal structure of SARS-CoV-2 3CLpro/Mpro bound to its inhibitor named N3. Inhibitors
are located at the two substrate binding sites. Two protomers, A and B, are presented in green and
purple. Image obtained by Jin et al., 2020 [57], PDB entry: 6LU7.
Inhibition of 3CLpro prevents replication of the virus, which makes this protease an
ideal therapeutic target. i ro from SARS-CoV-2
is about 96% compared to the one from SARS-CoV with a diff rence in only 12 out of
303 positions in the amino acid s quence. Crystal structures of SARS-CoV and SARS
CoV-2 main proteases showed th t th active sites of these nzymes are conserved [58].
Considering there is igh h mology b twe n the tw proteases, it is plausible to speculate
that effective inhibitor discovered for 3CLpro from SARS-C V would also be effective
against the same protease from SARS-CoV-2.
3.1.3. PLpro
Along with its protease activity, PLpro can modulate the innate immune response
by cleaving ubiquitin and interferon-stimulated gene 15 (ISG15), known regulators of
host innate immune pathways. Amino acid sequences of PLpro from SARS-CoV and
SARS-CoV-2 are 83% identical. Interestingly, PLpro from SARS-CoV and SARS-CoV-2
do not have the same specificity. The one from SARS-CoV acts more specifically on
ubiquitinated substrates, and the one from SARS-CoV-2 preferentially acts on ISG15-
conjugated substrates. Inhibition of this protease stops viral replication [59]. The structure
of PLpro from SARS-CoV 2 is presented in Figure 5.
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This protein is slightly basic, and it contains a high amount of Cys residues. Cys111 is
part of the catalytic triad that is formed from Cys111, His272, and Asp286. Additionally,
there are four Cys residues involved in the coordination of Zn ion that is very important for
the enzyme structure and six more Cys residues located through the enzyme. The enzyme
has a structure similar to ubiquitin-specific proteases composed of “thumb–palm–fingers”
catalytic domain and N-terminal ubiquitin-like domain. Zn ion is located in the fingers
subdomain and is coordinated by Cys189, 192, 224, and 226, while the catalytic site of this
enzyme is located at the interface of palm and thumb subdomains [60].
3.2. Antiviral Activity of Polyphenols
The increasing trend of scientific interest in polyphenol activities over the past two years
has resulted in the investigation of several strategies pertaining to their antiviral effect
against SARS-CoV-2. Vaccines for the prevention of COVID-19 have significantly lowered
the burden of disease management. Still, pharmacological treatment options are incessantly
being tested [61]. Despite concerted efforts invested in the development of new drugs, it
is well-known that the time lapse between the drug discovery and its clinical approval
might be long. Subsequently, repurposing of existing drugs might serve as a better alter-
native. To date, several screening efforts have been performed in an attempt to identify
both drug repurposing targets and possible antiviral compounds among those already
in use for other purposes [62,63]. A recently published drug repurposing study screened
more than 1400 FDA-approved drugs and compounds using artificial intelligence-powered
morphological analysis of several human cells lines during infection with SARS-CoV-2.
They identified 17 candidate compounds including one dietary supplement, that have
been shown to block or reduce SARS-CoV-2 infection in cells [64]. In this context regard-
ing the potential anti-SARS-CoV-2 activity, polyphenols, common dietary supplements
have also been proposed as one of the alternatives to combat against this global health
crisis [27,65,66].
In addition to their well-known antioxidative, anti-inflammatory, and immunomodu-
latory properties tending to influence viral infection outcomes by upregulating the body’s
immune system [67], polyphenols’ direct anti-SARS-CoV-2 activity has also been reinforced
due to their demonstrated inhibitory action against replication in other coronaviruses, such
as SARS-CoV and MERS-CoV [23]. Interactions of polyphenol with viral proteins and/or
host cell receptors may interfere with the entry of the virus and its replication in the host
cell (Figure 6). In this regard, the greatest focus has been put on the inhibition of viral
proteases and the prevention of S protein-ACE2 interaction.
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The numerous computational approaches carried throughout the emergence of the
novel coronavirus speculated on the potential of different polyphenols to interact with
SARS-CoV-2 viral proteins, thus, providing a platform for future in vitro and in vivo
studies. Besides in silico analyses, the antiviral effect of polyphenols has also been demon-
strated in vitro. Polyphenols may directly disrupt the life cycle of viruses by binding to
their selected essential proteins. These interactions could either inhibit viral enzymes,
such as 3CLpro or disturb the binding of viral structural proteins, for example, S protein,
to host cell proteins. Polyphenols have also shown to affect expression levels of differ-
ent proteins, which could also aid to their antiviral effect [6,68]. Previously discovered
protein targets for polyphenols include viral proteins, such as 3CLpro and S protein, and
some of the host cell proteins, including TMPRSS2, SIRT1, ACE2 receptors, and dipeptidyl
Peptidase 4 (DPP4) [27]. Although, DPP4 is another host cell receptor for the SARS-CoV-2
virus, its binding affinity for S protein is weaker than that of the ACE2 receptor. The
clinical data regarding the usage of DPP4 inhibitors and/or their potential adverse effect
on patients with COVID-19 is scarce [69].
The following section will give an overview of in vitro data obtained so far on the
effects of various polyphenols on main viral protein targets. Obtained in vitro IC50 values
for different polyphenols against 3CLpro and PLpro are given in Table 2.
3.2.1. CLpro/Mpro and PLpro as Targets
Having no closely related homolog in humans, the main protease of SARS-CoV-2
(Mpro/3CLpro) has been an important target for drug development due to its crucial role in
polyprotein processing and virus maturation [57]. To date, numerous polyphenols from
different natural sources with recognized antiviral activities have been screened in silico
for their potential to inhibit SARS-CoV-2 Mpro activity.
Among several polyphenols investigated in the study by Ghosh et al., epigallocatechin-
3-gallate (EGCG), epicatechin-gallate, and gallocatechin-3-gallate demonstrated good
binding affinity toward Mpro while also being able to interact with one or both of its
catalytic residues (His41 and Cys 145) by hydrogen bonding. As revealed by molecu-
lar dynamics (MD) simulations, formed complexes were highly stable and less prone
to conformational fluctuations in comparison to the unligated enzyme [68]. In another
study, Singh and coauthors identified three structurally similar polyphenolic compounds,
namely mangiferin, glucogallin, and phlorizin, as potential Mpro and host protein TMPRSS2
protease inhibitors. Molecular docking showed good binding affinities, while the MD sim-
ulation study predicted that these compounds could significantly stabilize the binding
cavity of the Mpro and TMPRSS2 of SARS-CoV-2, thus possibly preventing virus matu-
ration and S protein priming [70]. A comprehensive in silico study by Vijaykumar and
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coauthors identified 30 compounds capable of interfering with activation/dimerization of
the Mpro and 40 compounds acting at Mpro regulatory sites, thus possibly lowering enzyme
efficiency [71].
While in silico approaches do not necessarily guarantee antiviral behavior, they encour-
age and pave the way for future in vitro and in vivo studies, particularly if performed with
ligands containing proven antiviral activities towards homolog proteins of SARS-CoV-1
and other viruses. For instance, quercetin, a water-soluble flavonoid, is a well-established
antiviral agent for dengue and influenza A viruses [72,73]. Quercetin and its naturally
occurring and synthetic analogs have displayed inhibitory activity towards the Mpro of
SARS-CoV. Quercetin-3-β-galactoside has also been identified as a protease inhibitor [74].
Among natural compounds tested in silico for their interactivity with SARS-CoV-2 Mpro,
RNA dependent RNA polymerase (rdrp) and S protein, quercetin showed strong inter-
actions with Mpro and the receptor-binding domain of the S protein [71]. Evidently, in
yet another study conducted by Abian and colleagues, quercetin inhibited the activity of
Mpro from the SARS-CoV-2 virus. The inhibition constant, Ki, was calculated to be 7 µM,
justifying quercetin as a potent enzyme inhibitor. The dissociation constant determined
by isothermal calorimetry was 2.7 µM in the absence of NaCl and 10 µM in the presence
of 150 mM NaCl [75]. Despite a high homology between the SARS-CoV and SARS-CoV-2
main proteases, IC50 concentrations for the same polyphenol could still differ, for instance,
quercetin has an IC50 of 73 ± 4 µM for the main protease in SARS-CoV [76] and 21 µM for
the main protease in SARS-CoV-2 [75]. Docking simulation scores were also different for
these two proteases.
Along with inhibitory activity against Mpro, quercetin also inhibited recombinant
human ACE2 of SARS-CoV with IC50 values similar to those for the inhibition of viral Mpro
protease. The inhibition was time-dependent wherein shorter incubation times resulted in
higher inhibitory activity. This is not a desirable effect since inhibition of ACE2 is shown to
impact negatively on viral recovery [77] and hence highlights the need for a comprehensive
analysis of any polyphenol with potential antiviral activity. It is essential to investigate
their exact mode of action and whether their anti-inflammatory abilities could surpass the
pro-inflammatory effect due to inhibition of ACE2 activity [78].
Flavonoids herbacetin, rhoifolin, and pectolinarin were previously found to be effec-
tive inhibitors of Mpro of SARS-CoV. Using FRET-based assay, IC50 values of compounds
were determined and were 33.17, 27.45, and 37.78 µM, respectively. They were predicted to
bind at the active site of the main viral protease [79]. This study was continued with the
screening of the flavonoid library for inhibitory actions against SARS-CoV-2 Mpro activity,
and it was discovered that herbacetin, pectolinarin, and baicalin block the proteolytic
activity of SARS-CoV Mpro [80].
Tannic acid was revealed to be another potential natural drug against SARS-CoV-2.
This polyphenol acts as a dual inhibitor, inhibiting both Mpro and host cell protease
TMPRSS2. By using surface plasmon resonance (SPR), tannic acid illustrated binding
to Mpro with a dissociation constant of 1.1 µM and TMPRSS2 with a dissociation constant
of 1.77 µM. The concentration of tannic acid required to inhibit 50% of the proteases activity,
IC50, was 13.4 µM for Mpro and 2.31 µM for TMPRSS2. As assessed by luciferase reporter
assay, tannic acid also proved to inhibit the entrance of SARS-CoV-2 pseudovirus in the
human embryonic kidney cell line 293T which firmly expresses the recombinant human
ACE2 receptor and in African green monkey kidney Vero E6 cells. Favorably, tannic acid
showed little to no cytotoxicity towards tested cells [81].
Curcumin, being already explored in vitro as a potent inhibitor of SARS-CoV Mpro
with an IC50 value of 20 µM [82], is considered a promising natural polyphenol for miti-
gating the severity of COVID-19 disease. Indeed, the concentrations of curcumin above
30 µg/mL reduced the activity of SARS-CoV 2 Mpro by more than 50%, while the higher
concentration of 75 µg/mL produced residual activity of 28.1% [83]. Besides Mpro, this
molecule can also inhibit PLpro from SARS-CoV, with an IC50 of 5.7 µM [82]. In a recent
study, docking simulation showed that curcumin might covalently bind to Cys111 in
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the active site of PLpro by Michael’s addition reaction, thus inhibiting this enzyme [84].
Curcumin-loaded nanocarriers aimed to increase its bioavailability are currently being ex-
plored as antiviral alternatives. They are proposed to enhance curcumin bioavailability and
act as antiviral agents themselves, possibly displaying synergistic effects in combination
with curcumin [85].
Eckol and dieckol, phlorotannins isolated from edible brown algae Ecklonia cava, inhib-
ited Mpro from SARS-CoV. The cell-free, FRET-based assay showed that these two compounds
had IC50 values of 8.8 ± 3.5 and 2.7 ± 0.6 µM towards Mpro from SARS-CoV, respectively.
On the other hand, the cell-based inhibition assay, or the so-called cis-cleavage assay,
showed that only dieckol effectively inhibited Mpro with an IC50 of 68.1 ± 2.2 µM. The
explanation for this could be that this compound penetrates the cellular membrane more
effectively and reaches Mpro better than eckol [86]. Based on these results, their potential
as effective competitive inhibitors for SARS-CoV-2 Mpro has been suggested [66].
EGCG, the primary polyphenol of green tea, has been identified as a potential inhibitor
of SARS-CoV-2 Mpro in the recent in silico molecular docking study [68], with its antiviral
effect later being demonstrated in vitro as well. In support of the claims mentioned above
about differences in the behavior of the same polyphenol against SARS-CoV and SARS-CoV-
2 enzymes, the inhibition efficiency of EGCG towards Mpro from SARS-CoV was different
than the one towards Mpro from SARS-CoV 2. In their study, Nguyen and colleagues
found that epigallocatechin gallate and especially gallocatechin gallate were more potent
inhibitors of Mpro from SARS-CoV [76] than the same protease from SARS-CoV-2 [87]. It
should be noted that the authors used recombinant SARS-CoV Mpro expressed in P. pastoris
and SARS-CoV-2 Mpro expressed in E. coli, a factor that could influence obtained results. In
a study by Jang and coauthors, EGCG and theaflavin, the primary polyphenol in black tea,
inhibited the activity of Mpro of SARS-CoV-2 with IC50 of 16.5 µM for EGCG and 14.9 µM
for theaflavin. The authors used Mpro expressed in E. coli and FRET-based protease assay
for enzyme activity. As EGCG is susceptible to oxidation, the inhibitory activity of its
auto-oxidation products was also examined. Notably, after 12 h of auto-oxidation of EGCG,
there was no significant impact on its inhibitory activity. However, the inhibitory activity
of EGCG has decreased following 24 h oxidation, although some of the inhibitory effect
was still retained. Considering that maximal physiologically obtainable concentrations
of EGCG and theaflavin are significantly lower than their IC50 values, retention of some
of the EGCG inhibitory activity even after 24 h might be beneficial for potential antiviral
activity of EGCG. Moreover, the authors have also explored whether the combined use
of EGCG and theaflavin has a synergistic effect on inhibition of Mpro activity but showed
only an additive effect [88].
In a study investigating the inhibitory activity of 49 polyphenols towards SARS-CoV-2
Mpro, besides already mentioned tannic acid, isoflavones puerarin and daidzein and
flavonol myricetin were found to be potent inhibitors of this enzyme with IC50 values
of 42, 56, and 43 µM, respectively. In addition, their mixtures with tannic acid proved
to be effective as well. This may be a helpful finding since it reduces each polyphenol’s
required amount for obtaining the desired effect [87]. In a study by Xiao et al., myricetin
was also identified in vitro as a potent inhibitor of Mpro but with an order of magnitude
lower IC50 value of 3.684 ± 0.076 µM. Molecular docking showed that myricetin could
bind at the active site of Mpro. Additionally, myricetin improved bleomycin-induced
pulmonary inflammation, suggesting that it may be used both as an antiviral drug and
for symptomatic treatment of COVID-19 [89]. Myricetin has also shown potent inhibitory
activity towards SARS-CoV-1 nsP13 helicase, together with scutellarein. They were able to
inhibit ATPase activity but not DNA unwinding activity of viral helicase. ATPase activity
was determined by measuring the formation of inorganic phosphate in a colorimetric assay
using molybdate [90]. Whether these two flavonoids could inhibit the activity of helicase
from SARS-CoV-2 remains to be seen.
Different IC50 values for EGCG obtained by Nguyen et al. and Jang et al. and those
for myricetin obtained by Nguyen et al. and Xiao et al. indicate that experimental results
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should be interpreted cautiously since differences in experimental setup could significantly
influence obtained results.
Chalcone isolated from Angelica keiskei, named xanthoangelol E, was shown to be
an effective inhibitor of both Mpro and PLpro proteases of SARS-CoV with IC50 values of
11.4 µM and 1.2µM, respectively. These values were obtained using recombinant E. coli
enzymes and an inhibitory FRET assay. Chalcone competitively inhibited Mpro, while
PLpro was inhibited in a non-competitive manner. The calculated IC50 concentrations were
below CC50 (50% cytotoxic concentration), which for this polyphenol was determined
to be 65.6 µM [91]. Isolated polyphenols from Broussonetia papyrifera, broussochalcone
A, broussochalcone B, papyriflavonol A, 3′-(3-methylbut-2-enyl)-3′,4,7-trihydroxyflavane,
4-hydroxyisolonchocarpin, kazinol A, kazinol B, kazinol F, kazinol J, and broussoflavan
A were tested as potential inhibitors of both Mpro and PLpro proteases of SARS-CoV. In
general, tested polyphenols were more potent inhibitors of PLpro, with papyriflavonol A
being the best with a calculated IC50 of 3.7 µM for this enzyme. On the other hand, the best
inhibitor of Mpro was 3′-(3-methylbut-2-enyl)-3′,4,7-trihydroxyflavane [92].
Ethanol extract from Psoralea corylifolia seeds was shown to have inhibitory activity
towards SARS-CoV PLpro with IC50 value of 15 µg/mL. Further analysis showed that this
extract contained six phenolic compounds: bavachinin, neobavaisoflavone, isobavachal-
cone, 4′-O-methylbavachalcone, psoralidin, and corylifol A. All of these compounds were
reversible, mixed type inhibitors for PLpro, with IC50 values of 38.4 ± 2.4, 18.3 ± 1.1,
7.3 ± 0.8, 10.1 ± 1.2, 4.2 ± 1.0, and 32.3 ± 3.2 µM, respectively [93].
To the best of our knowledge, currently, there are no in vitro data on the antiviral
activity of polyphenols towards PLpro of SARS-CoV-2. A noticed lack of in silico studies
has been attributed to the paucity of known small molecule inhibitors of SARS-CoV-2
PLpro as well as the lack of structural conformation of the SARS-CoV-2 PLpro binding site
when bound to conventional inhibitors [94]. A molecular dynamics simulation study by
Huynh and coauthors suggested that chances for drug repurposing might be low in case of
PLpro [95]. Therefore, polyphenols with inhibitory activity against SARS-CoV PLpro might
not be as effective against SARS-CoV-2 PLpro.
Table 2. In vitro IC50 values for different polyphenols against 3CLpro and PLpro.
Enzyme Polyphenol IC 50 (µM) ReferenceSARS-CoV SARS-CoV-2
3CLpro
Quercetin 73 ± 4 21 [75,76]
Gallocatechin gallate 47 N/A [76]
Herbacetin 33.17 53.9 [79,80]
Rhoifolin 27.45 N/A [79]
Pectolinarin 37.78 51.64 [79,80]
Baicalin N/A 34.71 [80]
Tannic acid N/A 13.14 [81]
Curcumin 20 N/A [82]
Eckol 8.8 ± 3.5 N/A [86]
Dieckol 2.7 ± 0.6 N/A [86]
Epigallocatechin gallate 73 16.5, 171 ± 5 [76,87,88]
Theaflavin N/A 14.9 [88]
Puerarin N/A 42 [87]
Daidzein N/A 56 [87]
Myricetin N/A 43, 3.68 ± 0.08 [87,89]
Xanthoangelol E 11.4 N/A [91]
PLpro
Curcumin 5.7 N/A [82]
Xanthoangelol E 1.2 N/A [91]
Papyriflavonol A 3.7 N/A [92]
Bavachinin 38.4 ± 2.4 N/A [93]
Neobavaisoflavone 18.3 ± 1.1 N/A [93]
Isobavachalcone 7.3 ± 0.8 N/A [93]
4′-O-methylbavachalcone 10.1 ± 1.2 N/A [93]
Psoralidin 4.2 ± 1 N/A [93]
Corylifol A 32.3 ± 3.2 N/A [93]
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3.2.2. S Protein and S-ACE2 as a Target
An in-depth in vitro study by Goc and co-workers examined the effect of 56 polyphe-
nols on the binding of viral S protein for ACE2 receptor and its fusion for the cell membrane.
They showed that brazilin, theaflavin-3,3′-digallate, and curcumin had the strongest bind-
ing to the RBD domain of S protein. Both cell-based and cell-free experiments confirmed
this finding. These compounds were also able to reduce the fusion of cells expressing the
S protein to the human ACE2 overdressing cellular monolayer. Theaflavin-3,3′-digallate
and curcumin not only inhibit the ACE2 activity in both cell-free and cell-based assays
but also bind the human ACE2 receptor (hACE2) with moderate affinity. These effects
were not shown for brazilin. None of these three molecules affected the expression of
hACE2 in human alveolar epithelial A549 cells. Inhibition of host proteases, TMPRSS2 and
cathepsin L, was also observed, which is essential for cleavage of S protein and subsequent
viral fusion to host cell membrane [96].
Pomegranate peel extract in ethanol/water (70/30 v/v), rich in polyphenols, was inves-
tigated for its potential to inhibit SARS-CoV-2 activity by acting on viral S protein and ACE2
receptor. The abundant polyphenols in the obtained extract were ellagitannins punicalagin,
punicalin, granatin B, causarinin, galloyl-HHDP-hexoside, pedunculagin I, and pedun-
culagin II, punicalagin being the most abundant. Based on in vitro results, pomegranate
peel extract could bind to both S protein, presumably by interacting dominantly with
the RBD domain, and to ACE2 receptor, but with 10-fold lower affinity. Interaction be-
tween S protein and ACE2 was inhibited on a cellular level. By using S protein-carrying
Lentivirus, peel extract inhibited its entry into human kidney-2 cells. The extract was also
able to downregulate the expression of both ACE2 and TMPRSS2 [97]. Although both
proteins are involved in viral entry into the host cell, they also have an essential role in
metabolic processes, so their downregulation might prove to be the pitfall. It was noticed
that SARS-CoV infections and the S protein downregulate ACE2 expression, contributing
to the severity of lung pathology [77].
Anthraquinone emodin, produced in higher levels in Rheum and Polygonum genus,
effectively blocked the interaction between SARS-CoV S protein and ACE2 receptor. The
compound inhibited the binding of S protein to ACE2 coupled to the microtiter plate in
a competition ELISA assay, with an IC50 value of 200 µM. It also blocked the binding of
S protein to Vero E6 cells expressing ACE2. Infectivity of S protein-pseudotyped retrovirus
to ACE2-expressing Vero E6 cells was also reduced. Inhibition of viral infectivity for 50 µM
of emodin was 94.12 ± 5.90% [98]. Emodin has emerged as a potential anti-SARS-CoV-2
compound in a comprehensive drug repurposing screening [62]. A recent molecular dock-
ing study dealing with the mechanistic investigation of the interaction between SARS-CoV
S protein and emodin proposed that emodin could bind at the interface of two interacting
proteins, thus destabilizing their interaction. A similar surface pocket was found at the
contact surface of the SARS-CoV-2 S protein–ACE2 complex, providing evidence of the
possibly similar activity of emodin against SARS-CoV-2 [99].
Among polyphenols investigated for their anti-SARS-CoV-2 activity, a great interest
has been put on resveratrol. Its antioxidant and anti-inflammatory activities, particularly
concerning cardiovascular health, have been reviewed extensively [100,101]. Along with
its beneficial cardiovascular effects that may potentially reduce COVID-19 illness severity
in patients having cardiovascular complications [102], resveratrol was also shown to
directly interfere with the main pathways involved in SARS-CoV-2 pathogenesis including
expression of ACE2 and regulation of the renin-angiotensin system [103]. In addition, the
antiviral activity of resveratrol has been well documented against RNA viruses such as
influenza virus, rhinovirus, Zika virus, and MERS-CoV [104–107]. Antiviral activity of
resveratrol against MERS-CoV is associated with the promotion of cell survival and the
reduction of MERS-CoV-induced apoptosis [107]. Resveratrol upregulates the expression
of ACE2 in vascular smooth muscle cells stimulated by angiotensin II [108], which seems
to be beneficial for mitigation of COVID-19 disease, as ACE2 has organ-protective effects
in COVID-19 patients with poor prognosis [109]. A molecular docking study indicates that
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resveratrol binds to the S protein-ACE2 complex [110], which could be its inhibitory mode
of action. The direct anti-SARS-CoV-2 effect of resveratrol has also been reported in several
studies. Resveratrol was shown to inhibit the replication of SARS-CoV-2 in cultured Vero
cells (ATCC, CCL-81). By utilizing both qRT-PCR and immunofluorescence assay, an IC50 of
4.48 µM was determined. Interestingly, resveratrol exerted higher inhibitory activity after
the previous infection of cells with the virus. It was suggested that resveratrol could block
viral entry into the cells [111]. In line with this, upon treatment with resveratrol, a reduced
viral titer of SARS-CoV-2-infected Vero cells was reported by Pasquereau et al. with an IC50
value of 10.66 µM without significantly affecting cell viability [112]. Ter Ellen et al. showed
that both resveratrol and its metabolically more stable dimethylated structural analog,
pterostilbene, inhibited the replication of SARS-CoV-2 in air–liquid interface cultured
human primary bronchial epithelial cells up to 48 h post-infection. Pterostilbene even
inhibited SARS-CoV-2 replication more effectively than resveratrol [113]. Pterostilbene’s
improved biological activities compared to resveratrol have been ascribed to its dimethyl
ether structure, which increases its lipophilicity, thus limiting its glucuronidation and
sulfation and improving solubility, absorption, and bioavailability [114].
EGCG, previously mentioned as a potential Mpro inhibitor, has also been shown to
interact with viral S protein subunits, including S2 and RBD domains of both original and
UK strain mutant virus, thus interrupting interaction with ACE2. EGCG binds to the RBD
domain of the UK strain mutant slightly more effectively [115].
In vitro cytotoxic test using Vero E6 cells showed that phenols ferruginol and 7β-
hydroxydeoxycryptojaponol were able to abolish the cytopathogenic effect of SARS-CoV 1
at concentrations of 10 and 20 µM. These phenols inhibited viral replication in the same
cells, with IC50 values being 1.39 and 1.15 µM, respectively. Obtained IC50 values for
the inhibition of viral replication were much lower than their CC50 values, 80.4 µM for
ferruginol and 127 µM for 7β-hydroxydeoxycryptojaponol [82]. It remains to be seen if
ferruginol is also effective against SARS-CoV-2.
4. Clinical Studies on the Role of Polyphenols in the Treatment of COVID-19 Patients
In a race to prevent the spread of COVID-19 and to stop the global pandemic, it is no
surprise that many researchers and MDs have turned their attention to natural compounds,
which are safe for humans and have a history of therapeutic usage. Therefore, other than the
drugs being tested in clinical trials such as hydroxychloroquine, favipiravir, remdesivir, and
lopinavir/ritonavir [116], well-characterized polyphenolic compounds with previously
established anti-viral and anti-inflammatory properties are also among the candidates
evaluated for COVID-19 treatment or prophylaxis.
4.1. Green Tea Polyphenols as an Addition to Standard of Care Therapy for COVID-19
The lack of therapies for COVID-19 patients with mild and moderate symptoms
compelled a group of researchers from the Istituto Nazionale Biostrutture e Biosistemi,
Italy, to use standardized polyphenolic green tea extract during the lockdown in Italy in
Autumn 2020 [117] to treat ten symptomatic COVID-19 patients with positive nasopharyn-
geal swab tests for the SARS-CoV-2 virus. The group already had experience in green tea
extract application and dosage in animal [118] and clinical studies [119] related to vascular
and cancer disease. The green tea extract they chose for the COVID-19 study was Theaphe-
non E (ThE), the improved or new version of the Polyphenon E (PoE) manufactured by
the Mitsui Norin Co., Ltd., Shizuoka 426-0133 Japan, which is composed mainly of green
tea catechins (85–95%) out of which EGCG accounts for 65–70% of the total catechins [120].
PoE has been used in 35 clinical trials in the U.S. (Medicine) and was approved by the U.S.
FDA in 2006 as a tropic drug for warts caused by the papilloma virus [121]. The therapy
lasted for 15 days and consisted of two sessions of inhalation (0.3% ThE in 5 mL sterile PBS
pH 5.8 per nebulization session, 19 mg/day of EGCG) plus three capsules per day (300 mg
ThE/capsule or 595 mg/day of EGCG) accounting for a total of 840 mg of catechins or
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595 mg of EGCG per day, which was below the safety threshold limit suggested by the
European Food Safety Agency of 800 mg of EGCG per day [122].
Before testing the efficacy of ThE on COVID-19 patients, Bettuzzi et al. [117] tested the
proposed therapy in two healthy volunteers with no side effects. All COVID-19 patients
started the ThE therapy at a median of 5 days within a range of 3–6 days. Blood samples
were taken by their family doctor at the study enrollment date (day 0) and later when the
symptoms were gone at a median of 9 days (range of 7–15 days). Seven patients were
negative in a SARS-CoV-2 swab test at a median of 9 days (range of 6–13 days), 1 out of
the 3 still swab-positive patients had a very low viral load. At the end of the therapy the
inflammation markers monitored in the study had significantly decreased: α-1 anti-trypsin,
C-reactive protein and eosinophils in all patients, IL-6 and erythrocyte sedimentation
rate in 7 out of 10 patients. The authors compared the efficacy of the proposed treat-
ment with the study data reported by Manusco et al. [123], who followed 4480 patients
with a positive SARS-CoV-2 swab test in Italy from 26 of February to 22 of March 2020.
Manusco et al. [123] reported that at day 10, 0.7% of the patients had a first negative swab
test, with the percentage increasing to 19.0% on day 20. It seems that green tea polyphenol
treatment might have helped clear the virus from the patients, as 20% of patients from the
Bettuzzi et al. study [117] had the first negative swab at 10 days, increasing to 70% at day 20
from the first swab. As the authors declared, the effect of green tea polyphenols was notice-
able, as the probability of this happening by chance was p < 0.0023 at day 10 or p < 0.005
at day 20 (one-tailed Fisher-Yates test performed by the authors of the study), but the
mechanism was unknown. As thoroughly discussed above in our paper, anti-inflammatory
and anti-viral effects of green tea polyphenols are known, and there is a growing body
of computational and in vitro data suggesting the formation of specific interactions with
SARS-CoV-2 proteins, it seems to us that the key to the success of this study was the way
the polyphenols were delivered: at high dose, orally, targeting the SARS-CoV-2 infection
in the gastrointestinal tract, and at a lower dose, pulmonary, targeting the virus and the
immune response in lungs directly. The administration of green tea polyphenols through
inhalation is not new. It was safely administered to 48 elderly and hospitalized patients
with methicillin-resistant Staphylococcus aureus infection in a study by Yamada et al. [124].
To further clarify if green tea polyphenols can aid in speeding up the recovery and pre-
venting the death of COVID-19 patients, a clinical trial with a higher number of enrolled
subjects is required.
4.2. Curcumin with Piperine as an Addition to the Standard of Care Therapy for COVID-19
As discussed previously in the paper, curcumin from turmeric might be beneficial in
treating COVID-19. There are preclinical and clinical studies showing its positive effect on
the treatment of many disorders, including but not limited to gastrointestinal, inflammatory,
respiratory, and cardiovascular diseases [125,126]. A group from India performed a double-
blind, randomized, controlled trial (CTRI/2020/05/025482) in a COVID-19 dedicated
hospital in Maharashtra, India, from July to September 2020, publishing the study results
in May 2021 [127].
The group recruited adult symptomatic patients with a positive antigen test, further
randomly divided into a control and study group, each accounting for 70 patients. To
equalize the distribution of patients to the natural occurrence of mild, moderate, and
severe symptoms, according to their pilot study, each group had 30 patients with mild,
25 with moderate, and 15 with severe symptoms. Patients with mild symptoms had oxygen
saturation SpO2 > 94%, those with moderate symptoms had SpO2 between 90 and 94 and
pneumonitis, and severely ill were those with SpO2 < 90%. In addition to the standard of
care for COVID-19 in India, the control group received a probiotic capsule, and the study
group received a dietary supplement of curcumin in the form of Curcumin C3 Complex®
(SamiDirect, Bangalore, India) approved for human use by the U.S. FDA, together with an
absorption adjuvant piperin (Bioperine®, SamiDirect, Bangalore, India). The therapy lasted
for 14 days, during which 525 mg of curcumin and 2.5 mg of piperine were administered
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orally 2 times a day. Serology testing for complete blood count, C-reactive protein (CRP),
and D-dimer was performed on admission and later if required.
Overall, the authors show that patients from the study group recovered earlier from
COVID-19 symptoms than patients in the control group, with less deterioration of their
condition over their period of the hospital stay and better oxygen saturation on room
air with less patients needing oxygen therapy or mechanical ventilation. In the patients
with mild symptoms, curcumin treatment significantly reduced the number of days the
patients had SpO2 less than 94%, the number of patients requiring oxygen treatment, and
the number of patients with a neutrophil/lymphocyte ratio of less than 3.5. CRP and
D-dimer were maintained in this subgroup at the admission level, with no significant
rise in each of them. Apart from significantly maintaining the oxygen saturation levels
above 94% in patients with moderate symptoms, curcumin also significantly reduced the
number of patients who required the use of COVID-19 awake repositioning/proning
protocol, the number of patients requiring low molecular weight heparin, and the number
of patients requiring remdesivir. D-dimer was maintained at the admission level, and
there were significantly less patients with increased CRP levels. The numbers were not as
pronounced in the severely ill patients, suggesting that the treatment might not work in
this study subset.
Clinical data from this study are provided in detail as it was a study performed in a
hospital. However, there are some data that could help us in understanding the mechanism
of action that are missing, such as IL-6 levels, prothrombin time, and swab tests, but
considering that the authors had limited resources, that is understandable. The most
pronounced results from this study are the effect of treatment on oxygen saturation and
D-dimer levels in patients with mild and moderate COVID-19 symptoms. Curcumin is
known for its antithrombotic effects, and as the authors suggest, it might be considered for
use with other blood thinners used in COVID-19 treatment protocols. When comparing
this clinical study to the one described above, it seems that curcumin is less potent than
green tea catechins against COVID-19, but that needs to be further elucidated using the
same or similar study strategy and population size.
As the data from the in vitro studies are accumulating, and different animal models
are being developed [128], we should be seeing more reports on the in vivo effects of
polyphenolic compounds on SARS-CoV-2 infection and more clinical trials where they
are used as an adjuvant therapy. So far, we have found only one publication in the
form of a letter where authors tested Pudilan Xiaoyan Oral Liquid, a traditional Chinese
medicine containing four herbs (Indigowoad Root (Isatis indigotica), Bunge Corydalis
(Corydalis bungeana), Mongolian Dandelion (Taraxacum mongolicum), Scutellaria Amoena
(Scutellaria baicalensis)) and more than 180 ingredients, including polyphenols in a mouse
model. The herbal mixture exhibited potent anti-SARS-CoV-2 activity in infected hACE2
mice [129].
5. General Protective/Preventive Effects of Polyphenols in Diseases
Related to COVID-19
COVID-19 induces numerous pathophysiological manifestations affecting respiratory,
immune, hematological, renal, nervous, and gastrointestinal (GI) systems [27,130]. Pre-
existing chronic diseases, specifically cardiometabolic impairments and obesity, represent
risk factors linked to poorer prognosis in COVID-19 patients. Complications accompanying
COVID-19 can lead to organ dysfunction, metabolic acidosis, sepsis, blood coagulation dys-
function, cardiac arrest, and death [25]. Polyphenols and polyphenol-rich plants have been
widely tested and used for the general treatment of COVID-19 [23,117,131,132]. An update
on completed or recruiting clinical trials based on plants, their isolated products, and func-
tional foods against COVID-19 is summarized in an article by Alam et al. (2021) [133]. The
protective effects of polyphenols against acute lung injury are highlighted in a review paper
by He et al. (2021) [134], while a review of clinical trials data by Santos et al. (2021) [29]
reinforces the potency of polyphenols in the treatment of COVID-19. Physiological func-
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tions affected by COVID-19 and related diseases that the consumption of polyphenols can
ameliorate are shown in Figure 7.
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Polyphenols, strong antioxidants, can neutralize the harmful reactivity of undesired
or overproduced reactive oxygen and nitrogen species (ROS and RNS) that arise during
metabolic processes in the organism. Under physiological conditions, approximately 2% of
the oxygen consumed by aerobic cells is directed towards the formation of ROS/ NS [26].
Polyphenols also influence several immuno odulatory pathways, thus regulating immu-
nity. Numerous epidemiological studies have documented positive effects of polyphe-
nols against the development of chronic diseases such as metabolic syndrome, diabetes,
hypertension, cardiovascular diseases (CVD), infections, asthma, cancer, neurodegenera-
tive diseases, and coagulopathies. By alleviating chronic disturbances and impairments,
polyphenols also act as antiaging agents. Many of them have been found to exterminate
senescent cells as well, therefore adjusting the inflammaging and immunosenescence [29].
Polyphenols have been confirmed as antimicrobial agents, affecting various levels of de-
fense mechanisms against pathogen invasion. In addition, polyphenols exert prebiotic,
pro-apoptotic, anti-proliferative, hormonal control [23], and anti-arthritic properties [135].
Thousands of polyphenolic compounds have been identified in various plant species [136].
Usually, a mixture of polyphenolic compounds is found in a plant, and a specific compound
may be located only in one plant compartment (root, stem, leaf, flower, seed) or in a number
of them. Polyphenol supplements are widely consumed as nutraceuticals. However, they
are traditionally absorbed via polyphenol-rich plants and their derivatives in the form of
juice, tea, and infusion. Polyphenols are constituents of functional foods. The main task of
functional foods is to strengthen physiological functions. Since polyphenols participate in
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redox reactions, one should bear in mind that their antioxidant capacity is reduced upon
improper or prolonged storage.
The bioavailability of each polyphenol differs, and there is no relation between its
quantity in a plant/food and bioavailability, as a complex process of deconjugation, hy-
drolysis, gastrointestinal absorption, and further transformation occurs in the body [137].
Polyphenols undoubtedly exert health-improving effects, but little is known about their
metabolic products or the exact metabolic mechanism of their action. Likewise, biological
properties differ greatly from one polyphenol to another [136]. Common to all of them is
the ability of the phenolic group to accept an electron, forming a relatively stable phenoxyl
radical, thus, interfering with cellular oxidation reactions. Polyphenol metabolites in blood
bind to proteins, particularly albumin. It is still unresolved whether the albumin-attached
polyphenols can also perform physiological actions or in their free form exclusively. The
half-life of polyphenols and their metabolites in the blood is short, as they are efficiently
removed. For example, the half-life of resveratrol is approximately 10 h [138]. To en-
hance their biological half-life, increase oral absorption, or render them efficient locally,
polyphenols are conjugated with other molecules, such as oligosaccharides [139], packed
in granules with lipids such as sunflower phospholipids [137], nanoencapsulated [140], or
prepared in a nasal spray form [141].
5.1. Preventive Effects of Polyphenol against Metabolic Syndrome and Diabetes
Metabolic syndrome and diabetes are associated with impaired glucose metabolism.
The most common consequences are glucose insensitivity, impaired insulin secretion,
obesity, various metabolic disturbances, inflammation, CVD, etc. Prolonged exposure
to high glucose concentration leads to structural changes of physiological molecules
(i.e., non-enzymatic glycosylation or glycation), formation of advanced-glycosylation end-
products (AGEs), and modification of cellular structures (e.g., membranes); afterward,
it might advance to irreversible retinopathy, nephropathy, and neuropathy. Diabetic ke-
toacidosis, hyperosmolar hyperglycemic condition, and acute metabolic complications
were recorded in patients with diabetes and COVID-19 [27]. According to the study by
Tessier et al. (2021) [130], acute hyperglycemia might enhance the entry of SARS-CoV-2 into
additional host cells via upregulation of the expression of angiotensin-converting enzyme
(ACE2) in other tissues. However, reduced expression of ACE2 was previously reported by
Reich et al. (2008) [142] in patients with diabetes type 2 and kidney dysfunction. Additional
clinical studies are essential to resolve the inconsistency in findings.
Polyphenols act by inhibiting intestinal glycosidases and glucose transporters, leading
to reduced glucose absorption in the gut. Catechin, epicatechin, epigallocatechin, epicat-
echin gallate, soybean isoflavones, tannic acid, chlorogenic acid, and saponins decrease
intestinal transport of glucose [143]. Additionally, polyphenols such as resveratrol exert
anti-diabetic effects by modulating the activity of sirtuins (SIRTs), NAD+ deacetylase,
which is responsible for the entire glucose homeostasis [144], and by improving insulin
sensitivity, possibly by affecting potassium channels in pancreatic beta-cells [145]. Ferulic
acid ameliorates glucose response to insulin [146], while quercetin can suppress lipid
peroxidation in diabetics [147]. Consumption of coffee and its most abundant polyphenol,
chlorogenic acid, stimulates phosphorylation of the insulin receptor and downstream
signaling pathways as well as major glucose transporter 4 gene, GLUT4, translocation, thus
increasing intracellular glucose utilization [148].
Obesity is recognized as a risk factor in COVID-19 patients. At least 25% of patients
who died in the United States following COVID-19 were obese [27]. Obese patients have a
higher risk of developing severe pneumonia and often require mechanical ventilation as
their respiratory mechanics is impaired [130]. Different cells in the adipose tissue secrete
adipokines, cytokines, and chemokines which contribute to the overall inflammatory reac-
tion. Polyphenols induce a reduction in body weight and adipose tissue inflammation [27].
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5.2. Preventive Effects of Polyphenol against Cardiovascular Diseases
Hypertension and atherosclerosis are the most common events that lead to CVD.
Atherosclerosis develops in arterial regions, which are affected by lesions. Atherosclerotic
plaque consists of lipids, calcium, fibrin, and other blood components over time, narrowing
the vessel and reducing the blood flow. The consequence is reduced oxygen and nutrient
supply to the affected organ, the most serious being when developed in the heart and brain.
One of the risk factors for atherosclerosis is the oxidation of low-density lipoproteins (LDL),
which easily adheres and forms plaques. Polyphenols efficiently inhibit this process; in
addition, they also contribute to preventing or ameliorating CVD by reducing inflammatory
effects, improving endothelial function, exerting anti-coagulation and anti-platelet action,
and increasing high-density lipoproteins.
Quercetin and resveratrol are among the most potent polyphenols in combat against
CVD. Quercetin was shown to inhibit the expression of matrix metalloproteinase 1 (MMP1)
and disrupt the atherosclerotic plaque [149]. Resveratrol inhibits LDL oxidation and the
activity of cyclooxygenase 1 (COX1), which is responsible for tromboxane A2 synthesis, a
molecule that acts as a vasoconstrictor and an activator of platelet aggregation [150]. Resver-
atrol is responsible for the “French Paradox” phenomenon: high-fat diet and smoking and
yet low incidence of CVD among the French.
5.3. Preventive Effects of Polyphenol against Coagulopathies
COVID-19 is associated with a high rate of thromboembolic complications [151–153].
The venous coagulopathy incidence was found to be significantly elevated in intensive
care unit (ICU) patients (around 45%) than in non-ICU patients (approximately 23%) and
much higher than in critically ill patients with other viral respiratory infections. After their
demise, autopsy studies of COVID-19 patients revealed pulmonary macroemboli, severe
endothelial injury, microemboli, and increased angiogenesis [153]. The strong procoagulant
stage is accompanied by an increased concentration of D-dimer (fibrinogen degradation
product) and enhanced platelet activation. Mechanisms underlying COVID-19 coagulopa-
thy are not yet fully understood, but the direct effects of the virus on pneumocytes and the
endothelium, local and systemic inflammation, and disturbances in the hemostasis plus
circulatory stasis from immobility seem to contribute to this complex interplay. The ad-
vanced stage of COVID-19 accompanied by thrombogenicity may lead to reduced platelet
count and deficiency of coagulation factors, thus increasing the risk of bleeding. Numerous
clinical trials investigate anticoagulant treatments [153], but definitive recommendations
are still awaited.
Polyphenols have shown an inhibitory effect on platelet activation pathways, such as
P2Y-ADP, glycoprotein VI-collagen, protease-activated receptor 1-thrombin, and COX1-
thromboxane [154]. The chlorogenic acid from cherries, apples, and plums; polyphenols
from pigmented rice (anthocyanins); and propolis-derived polyphenols have been found
to retain the antiplatelet effect [155]. Quercetin, cyanidin, silybin, cyanin, catechin, and
epicatechin inhibit thrombin amidolytic activity, among which the first three can also affect
its proteolytic activity [156,157]. Honokiol, a tree lignan, was identified as the most potent
polyphenol with anti-thrombin potential that can influence the activation of the SIRT family
of proteins [158,159].
5.4. Preventive Effects of Polyphenol against Neural Diseases
Oxidative stress is an underlying cause of many neurological and neurodegenerative
diseases. Neuro trauma can activate glial cells, neurons, and neuroimmune cells in the
brain, which induces the release of neuroinflammatory mediators, leading to neuronal
death and cognitive decline. Neuroinflammation of the brain can dysregulate respiratory,
cardiac, and renal functions [27]. There is still a lack of effective therapies to treat neu-
rodegenerative disorders. COVID-19 patients have commonly reported temporary sensory
impairment (smell and taste). Luteolin can suppress systemic neuroinflammation and
improve cognitive functions, and it was shown to be efficient in COVID-19 patients [160].
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It can act through several mechanisms, the most important being inhibition of COVID-19-
associated cytokine release from mast cells, an event involved in cytokine storm in severe
cases of SARS-CoV-2 infection.
5.5. Preventive Effects of Polyphenol against Respiratory Diseases
The respiratory system is heavily affected by COVID-19. Here, it is worth mention-
ing that respiratory diseases are often accompanied by narrowed or obstructed airways,
wherein increased consumption of apple and soybean polyphenols has been speculated to
improve lung function [161]. Patients with COVID-19 are vulnerable to reactivation of the
Herpes simplex 1 virus (HSV) infection causing secondary respiratory infection [162], and
polyphenols have been reported to exert anti-HSV activity. Polyphenols are now under
consideration as promising therapeutic agents against HSV viremia [163].
5.6. Preventive Effects of Polyphenol against Dysbalance in Gut Microbiota
The inflammation in the respiratory system may cause changes in gut microbiota [27].
The lung–gut axis appears to be crucial in respiratory diseases, especially during viral
infections, although the mechanism of interactions remains unclear. COVID-19 is also
associated with gastrointestinal disturbances such as diarrhea, nausea, and vomiting [164].
Application of probiotics and prebiotics, including polyphenols [165], might strengthen
the immune system and minimize the virus-associated respiratory tract damage [27]. Non-
digestible food ingredients that selectively promote the growth of functional bacteria have
beneficial effects on the intestinal lining. Polyphenol transformation by gut microbiota
results in metabolites that can both reduce pathogens and enhance favorable bacterial
strains. Intracolonic microorganisms are essential for polyphenol metabolism to produce
beneficial bioactive metabolites.
5.7. Polyphenols, Mediterranean Diet, and COVID-19
A typical lifestyle during the COVID-19 pandemic was lockdown, unhealthy diet,
physical inactivity, and anxiety. This newly embraced lifestyle contributed to increased
risk factors for numerous comorbidities. A Mediterranean diet consists predominantly
of fruits, vegetables, cereals, and fish, and it is associated with nutraceuticals such as
polyphenols, omega polyunsaturated fatty acids, vitamins, and minerals. A negative
correlation was observed between adherence to the Mediterranean diet and the number
of COVID-19-related deaths in 23 countries out of 25; Italy and Spain were profiled as
outliers in the study since they had unproportionally high mortality rates despite the high
Mediterranean adequacy index [166]. The governmental response, differences in health
care systems, and socio-cultural factors have contributed to the high death rate in these
populations regardless of their nutritional habits. This negative association was discovered
when the data were adjusted to link well-being factors (such as income, education, housing,
environment, and life satisfaction) and physical inactivity. Greene and coauthors stressed
that despite their listed limitations regarding their study and methodology, their findings
are still significant enough to venture further if the Mediterranean diet and other dietary
approaches could reduce the risk for COVID-19 comorbidities.
6. Polyphenol Based Phytomedicines
In addition to their intrinsic biological activity, naturally occurring polyphenols pro-
vide a solid base for the design of semisynthetic analogs with potentially improved bioac-
tivity. Knowledge of determinants influencing binding modes of polyphenols to pro-
tein targets is important from the aspect of designing functionally improved inhibitors.
Molecular modeling-assisted design of eight new derivatives of quercetin-3-β-galactoside
containing chemical modifications of its key binding determinants has previously helped
identify the structure-activity relationship of this type of inhibitor against SARS-CoV [74].
A similar approach could be explored in the case of SARS-CoV-2 proteins. For instance,
monocarbohydrate moiety in baicalin significantly influenced its binding mode to 3CLpro of
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SARS-CoV-2 in in silico study [80]. In regard to this, molecular docking studies have shown
the potential of two products, Linebacker and Equivir, to interfere with viral spike pro-
tein, helicase, and protease sites on ACE2 receptor, thus potentially blocking SARS-CoV-2
replication and infection. Linebacker, a synthetic, flavonoid-based compound, showed
the ability to bind to ACE2 receptor. Molecular docking showed that the binding energy
of Linebacker for ACE2 was higher compared to chloroquine which is currently being
investigated in clinical trials as a possible prophylactic and therapeutic in the treatment
of COVID-19. Phytomedicines based on mixtures of several naturally occurring polyphe-
nols are also being tested. For example, Equivir, a mixture of hesperetin, myricetin, and
piperine, has antiviral activity. Equivir acts by inhibiting intracellular adhesion molecule 1,
helicase, ATPase, neuraminidase, and polymerase, which reduces and prevents viral entry
and replication. All three polyphenolic components of Equivir are registered as Generally
Recognized as Safe (GRAS) by FDA [167].
7. Conclusions and Future Perspectives
Literature data about the protective role of plant phenolic compounds as molecules
against SARS-CoV-2 viral infection is on the rise, especially during 2021. Here, we reviewed
the most recent advances related to molecular mechanisms of possible action of pheno-
lic compounds in COVID-19 protection and prevention including the current views on
phenolic compounds intervention at least as an adjunct therapeutic support. This review
demonstrates that phenolic compounds may have several mechanisms of action against
SARS-CoV-2. In addition to their antioxidant activities, multiple cellular and molecular
pathways have been shown to be involved in their mechanism of action against different
chronic disorders. However, there is still a lack of studies on the effects and mechanisms of
in vivo-formed metabolites of phenolic compounds against SARS-CoV-2, although these
metabolites are increasingly recognized as the main acting components in situ.
Further clinical studies, primarily in vivo, are still crucial to assess the therapeutic
and pharmacological potential of phenolic compounds not just in the course but also
post COVID-19 infection. Moreover, specifically designed clinical studies are necessary to
understand individual variability of phenolic compounds action in COVID-19 infection,
particularly considering their bioavailability. The epidemiological studies demonstrat-
ing a correlation between daily consumption of phenolic compounds and prevention of
SARS-CoV-2 infection and development of complications would be valuable for nutritional
recommendations and their application as nutraceuticals to combat COVID-19. Expansion
of functional foods and pharmaceutical preparations based on phenolic compounds in
the last decade should be exploited to raise population awareness of the multifaceted
beneficial properties of phenolic compounds against COVID-19 and the significance of
phenolic compound-enriched/or supplemented nutrition. The low risk of phenolic com-
pounds interacting with concomitant pharmacological treatments and side effects make
these compounds safe and thus suitable for their inclusion in clinical practice via the oral
and respiratory routes by application of aerosol delivery systems.
Phenolic compounds-rich plant extracts have been in use since ancient medicine [168],
and they are promising aids in SARS-CoV-2 prevention and treatment, particularly due to
the synergistic effects of their components [169]; however, the standardization of extracts is
necessary as plant extracts consist of a series of different compounds occurring in varying
concentrations. In addition, further identification of individual phenolic compounds and
determination of their particular mechanisms of action and their synergistic, additive,
or complementary effects in COVID-19 prevention would be of great interest, although
it is challenging.
This review shows that, with their multiple-target mechanism of action, phenolic
compounds are promising adjuvants for prevention, treatment, and recovery strategies in
the fight against COVID-19 multisystem pathogens.
Int. J. Mol. Sci. 2021, 22, 12385 23 of 29
Author Contributions: Conceptualization, T.C.V.; writing—original draft preparation, N.G., M.R.,
O.N., M.S. and D.S.-V.; writing—review and editing, T.C.V., D.S-V. and U.K. All authors have read
and agreed to the published version of the manuscript.
Funding: This research work was funded by the Ministry of Education, Science and Technological De-
velopment of the Republic of Serbia, grant number: 451-03-9/2021-14/200168; the Serbian Academy
of Sciences and Arts, grant number F-26; and the European Commission, under the Horizon 2020,
FoodEnTwin Project, grant number: 810752.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Gupta, A.; Madhavan, M.V.; Sehgal, K.; Nair, N.; Mahajan, S.; Sehrawat, T.S.; Bikdeli, B.; Ahluwalia, N.; Ausiello, J.C.;
Wan, E.Y.; et al. Extrapulmonary manifestations of COVID-19. Nat. Med. 2020, 26, 1017–1032. [CrossRef]
2. Lai, C.-C.; Ko, W.-C.; Lee, P.-I.; Jean, S.-S.; Hsueh, P.-R. Extra-respiratory manifestations of COVID-19. Int. J. Antimicrob. Agents
2020, 56, 106024. [CrossRef]
3. Zheng, K.I.; Feng, G.; Liu, W.; Targher, G.; Byrne, C.D.; Zheng, M. Extrapulmonary complications of COVID-19: A multisystem
disease? J. Med. Virol. 2021, 93, 323–335. [CrossRef]
4. Dong, M.; Zhang, J.; Ma, X.; Tan, J.; Chen, L.; Liu, S.; Xin, Y.; Zhuang, L. ACE2, TMPRSS2 distribution and extrapulmonary organ
injury in patients with COVID-19. Biomed. Pharmacother. 2020, 131, 110678. [CrossRef]
5. Paraiso, I.L.; Revel, J.S.; Stevens, J.F. Potential use of polyphenols in the battle against COVID-19. Curr. Opin. Food Sci. 2020, 32,
149–155. [CrossRef]
6. Annunziata, G.; Sanduzzi Zamparelli, M.; Santoro, C.; Ciampaglia, R.; Stornaiuolo, M.; Tenore, G.C.; Sanduzzi, A.; Novellino, E.
May polyphenols have a role against coronavirus infection? An overview of in vitro evidence. Front. Med. 2020, 7, 240. [CrossRef]
7. Prasansuklab, A.; Theerasri, A.; Rangsinth, P.; Sillapachaiyaporn, C.; Chuchawankul, S.; Tencomnao, T. Anti-COVID-19 drug
candidates: A review on potential biological activities of natural products in the management of new coronavirus infection. J.
Tradit. Complement. Med. 2021, 11, 144–157. [CrossRef]
8. Pamuru, R.R.; Ponneri, N.; Damu, A.G.; Vadde, R. Targeting natural products for the treatment of COVID-19—An updated
review. Curr. Pharm. Des. 2020, 26, 5278–5285. [CrossRef]
9. Omokhua-Uyi, A.G.; Van Staden, J. Natural product remedies for COVID-19: A focus on safety. S. Afr. J. Bot. 2021, 139, 386–398. [CrossRef]
10. Huang, J.; Tao, G.; Liu, J.; Cai, J.; Huang, Z.; Chen, J. Current prevention of COVID-19: Natural products and herbal medicine.
Front. Pharmacol. 2020, 11, 588508. [CrossRef]
11. Chakravarti, R.; Singh, R.; Ghosh, A.; Dey, D.; Sharma, P.; Velayutham, R.; Roy, S.; Ghosh, D. A review on potential of natural
products in the management of COVID-19. RSC Adv. 2021, 11, 16711–16735. [CrossRef]
12. Quero, J.; Mármol, I.; Cerrada, E.; Rodríguez-Yoldi, M.J. Insight into the potential application of polyphenol-rich dietary
intervention in degenerative disease management. Food Funct. 2020, 11, 2805–2825. [CrossRef]
13. Serreli, G.; Deiana, M. In vivo formed metabolites of polyphenols and their biological efficacy. Food Funct. 2019, 10, 6999–7021. [CrossRef]
14. Dejani, N.N.; Elshabrawy, H.A.; da Silva Maia Bezerra Filho, C.; de Sousa, D.P. Anticoronavirus and immunomodulatory phenolic
compounds: Opportunities and pharmacotherapeutic perspectives. Biomolecules 2021, 11, 1254. [CrossRef]
15. del Carmen Villegas-Aguilar, M.; Fernández-Ochoa, Á.; de la Luz Cádiz-Gurrea, M.; Pimentel-Moral, S.; Lozano-Sánchez, J.;
Arráez-Román, D.; Segura-Carretero, A. Pleiotropic biological effects of dietary phenolic compounds and their metabolites on
energy metabolism, inflammation and aging. Molecules 2020, 25, 596. [CrossRef]
16. Matacchione, G.; Gurău, F.; Baldoni, S.; Prattichizzo, F.; Silvestrini, A.; Giuliani, A.; Pugnaloni, A.; Espinosa, E.; Amenta, F.;
Bonafè, M.; et al. Pleiotropic effects of polyphenols on glucose and lipid metabolism: Focus on clinical trials. Ageing Res. Rev.
2020, 61, 101074. [CrossRef]
17. Ofosu, F.K.; Daliri, E.B.M.; Elahi, F.; Chelliah, R.; Lee, B.H.; Oh, D.H. New insights on the use of polyphenols as natural
preservatives and their emerging safety concerns. Front. Sustain. Food Syst. 2020, 4, 525810. [CrossRef]
18. Quideau, S.; Deffieux, D.; Douat-Casassus, C.; Pouységu, L. Plant polyphenols: Chemical properties, biological activities, and
synthesis. Angew. Chem. Int. Ed. 2011, 50, 586–621. [CrossRef]
19. Kumar, N.; Goel, N. Phenolic acids: Natural versatile molecules with promising therapeutic applications. Biotechnol. Rep. 2019,
24, e00370. [CrossRef]
20. Tsao, R. Chemistry and Biochemistry of Dietary Polyphenols. Nutrients 2010, 2, 1231–1246. [CrossRef]
21. Shrestha, S.; Zhang, W.; Smid, S.D. Phlorotannins: A review on biosynthesis, chemistry and bioactivity. Food Biosci. 2021, 39,
100832. [CrossRef]
22. Guan, H.; Zhang, W.; Sun-Waterhouse, D.; Jiang, Y.; Li, F.; Waterhouse, G.N.; Li, D. Phenolic-protein interactions in foods and
post ingestion: Switches empowering health outcomes. Trends Food Sci. Technol. 2021, 118, 71–86. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 12385 24 of 29
23. Mehany, T.; Khalifa, I.; Barakat, H.; Althwab, S.A.; Alharbi, Y.M.; El-Sohaimy, S. Polyphenols as promising biologically active
substances for preventing SARS-CoV-2: A review with research evidence and underlying mechanisms. Food Biosci. 2021, 40,
100891. [CrossRef]
24. Chojnacka, K.; Witek-Krowiak, A.; Skrzypczak, D.; Mikula, K.; Młynarz, P. Phytochemicals containing biologically active
polyphenols as an effective agent against COVID-19-inducing coronavirus. J. Funct. Foods 2020, 73, 104146. [CrossRef] [PubMed]
25. El-Missiry, M.A.; Fekri, A.; Kesar, L.A.; Othman, A.I. Polyphenols are potential nutritional adjuvants for targeting COVID-19.
Phyther. Res. 2021, 35, 2879–2889. [CrossRef] [PubMed]
26. Pérez de la Lastra, J.M.; Andrés-Juan, C.; Plou, F.J.; Pérez-Lebeña, E. Impact of zinc, glutathione, and polyphenols as antioxidants
in the immune response against SARS-CoV-2. Processes 2021, 9, 506. [CrossRef]
27. Levy, E.; Delvin, E.; Marcil, V.; Spahis, S. Can phytotherapy with polyphenols serve as a powerful approach for the prevention and
therapy tool of novel coronavirus disease 2019 (COVID-19)? Am. J. Physiol.-Endocrinol. Metab. 2020, 319, E689–E708. [CrossRef]
28. Giovinazzo, G.; Gerardi, C.; Uberti-Foppa, C.; Lopalco, L. Can natural polyphenols help in reducing cytokine storm in COVID-19
patients? Molecules 2020, 25, 5888. [CrossRef] [PubMed]
29. Santos, J.C.; Ribeiro, M.L.; Gambero, A. The impact of polyphenols-based diet on the inflammatory profile in COVID-19 elderly
and obese patients. Front. Physiol. 2021, 11, 612268. [CrossRef]
30. Limanaqi, F.; Busceti, C.L.; Biagioni, F.; Lazzeri, G.; Forte, M.; Schiavon, S.; Sciarretta, S.; Frati, G.; Fornai, F. Cell clearing systems as
targets of polyphenols in viral infections: Potential implications for COVID-19 pathogenesis. Antioxidants 2020, 9, 1105. [CrossRef]
31. Mhatre, S.; Srivastava, T.; Naik, S.; Patravale, V. Antiviral activity of green tea and black tea polyphenols in prophylaxis and
treatment of COVID-19: A review. Phytomedicine 2021, 85, 153286. [CrossRef] [PubMed]
32. Park, J.; Park, R.; Jang, M.; Park, Y.-I. Therapeutic potential of EGCG, a green tea polyphenol, for treatment of coronavirus
diseases. Life 2021, 11, 197. [CrossRef] [PubMed]
33. Milenkovic, D.; Ruskovska, T.; Rodriguez-Mateos, A.; Heiss, C. Polyphenols could prevent SARS-CoV-2 infection by modulating
the expression of miRNas in the host cells. Aging Dis. 2021, 12, 1169. [CrossRef] [PubMed]
34. Liskova, A.; Koklesova, L.; Samec, M.; Abdellatif, B.; Zhai, K.; Siddiqui, M.; Šudomová, M.; Hassan, S.T.S.; Kudela, E.;
Biringer, K.; et al. Targeting phytoprotection in the COVID-19-induced lung damage and associated systemic effects—the
evidence-based 3PM proposition to mitigate individual risks. EPMA J. 2021, 12, 325–347. [CrossRef]
35. Del Bo’, C.; Bernardi, S.; Marino, M.; Porrini, M.; Tucci, M.; Guglielmetti, S.; Cherubini, A.; Carrieri, B.; Kirkup, B.; Kroon, P.; et al.
Systematic review on polyphenol intake and health outcomes: Is there sufficient evidence to define a health-promoting polyphenol-
rich dietary Pattern? Nutrients 2019, 11, 1355. [CrossRef]
36. Cardona, F.; Andrés-Lacueva, C.; Tulipani, S.; Tinahones, F.J.; Queipo-Ortuño, M.I. Benefits of polyphenols on gut microbiota and
implications in human health. J. Nutr. Biochem. 2013, 24, 1415–1422. [CrossRef] [PubMed]
37. Goszcz, K.; Deakin, S.J.; Duthie, G.G.; Stewart, D.; Leslie, S.J.; Megson, I.L. Antioxidants in cardiovascular therapy: Panacea or
false hope? Front. Cardiovasc. Med. 2015, 2, 29. [CrossRef]
38. Cuicchi, D.; Lazzarotto, T.; Poggioli, G. Fecal-oral transmission of SARS-CoV-2: Review of laboratory-confirmed virus in
gastrointestinal system. Int. J. Colorectal Dis. 2021, 36, 437–444. [CrossRef]
39. Da Luz, B.B.; de Oliveira, N.M.T.; dos Santos, I.W.F.; Paza, L.Z.; Braga, L.L.V.D.M.; Platner, F.D.S.; Werner, M.F.D.F.; Fernandes, E.S.;
Maria-Ferreira, D. An overview of the gut side of the SARS-CoV-2 infection. Intestig. Res. 2020, 19, 379–385. [CrossRef]
40. Blaser, A.R.; Gunst, J.; Arabi, Y.M. The gut in COVID-19. Intensive Care Med. 2021, 47, 1024–1027. [CrossRef]
41. Bennick, A. Interaction of plant polyphenols with salivary proteins. Crit. Rev. Oral Biol. Med. 2002, 13, 184–196. [CrossRef]
42. Davies, H.S.; Pudney, P.D.A.; Georgiades, P.; Waigh, T.A.; Hodson, N.W.; Ridley, C.E.; Blanch, E.W.; Thornton, D.J. Reorganisation
of the Salivary Mucin Network by Dietary Components: Insights from Green Tea Polyphenols. PLoS ONE 2014, 9, e108372.
[CrossRef] [PubMed]
43. Xu, H.; Zhong, L.; Deng, J.; Peng, J.; Dan, H.; Zeng, X.; Li, T.; Chen, Q. High expression of ACE2 receptor of 2019-nCoV on the
epithelial cells of oral mucosa. Int. J. Oral Sci. 2020, 12, 8. [CrossRef]
44. Perlman, S. Another Decade, Another Coronavirus. N. Engl. J. Med. 2020, 382, 760–762. [CrossRef] [PubMed]
45. Khailany, R.A.; Safdar, M.; Ozaslan, M. Genomic characterization of a novel SARS-CoV-2. Gene Rep. 2020, 19, 100682. [CrossRef] [PubMed]
46. Paraskevis, D.; Kostaki, E.G.; Magiorkinis, G.; Panayiotakopoulos, G.; Sourvinos, G.; Tsiodras, S. Full-genome evolutionary
analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event.
Infect. Genet. Evol. 2020, 79, 104212. [CrossRef]
47. Dhama, K.; Patel, S.K.; Sharun, K.; Pathak, M.; Tiwari, R.; Yatoo, M.I.; Malik, Y.S.; Sah, R.; Rabaan, A.A.; Panwar, P.K.; et al.
SARS-CoV-2 jumping the species barrier: Zoonotic lessons from SARS, MERS and recent advances to combat this pandemic virus.
Travel Med. Infect. Dis. 2020, 37, 101830. [CrossRef]
48. Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N.-H.;
Nitsche, A.; et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.
Cell 2020, 181, 271–280. [CrossRef]
49. Shang, J.; Wan, Y.; Luo, C.; Ye, G.; Geng, Q.; Auerbach, A.; Li, F. Cell entry mechanisms of SARS-CoV-2. Proc. Natl. Acad. Sci. USA
2020, 117, 11727–11734. [CrossRef]
50. Zhang, Q.; Xiang, R.; Huo, S.; Zhou, Y.; Jiang, S.; Wang, Q.; Yu, F. Molecular mechanism of interaction between SARS-CoV-2 and
host cells and interventional therapy. Signal. Transduct. Target. Ther. 2021, 6, 233. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 12385 25 of 29
51. Liu, C.; Zhou, Q.; Li, Y.; Garner, L.V.; Watkins, S.P.; Carter, L.J.; Smoot, J.; Gregg, A.C.; Daniels, A.D.; Jervey, S.; et al. Research and
development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent. Sci. 2020, 6,
315–331. [CrossRef]
52. Satarker, S.; Nampoothiri, M. Structural proteins in severe acute respiratory syndrome coronavirus-2. Arch. Med. Res. 2020, 51,
482–491. [CrossRef]
53. Huang, Y.; Yang, C.; Xu, X.F.; Xu, W.; Liu, S.W. Structural and functional properties of SARS-CoV-2 spike protein: Potential
antivirus drug development for COVID-19. Acta Pharmacol. Sin. 2020, 41, 1141–1149. [CrossRef]
54. Wrapp, D.; Wang, N.; Corbett, K.S.; Goldsmith, J.A.; Hsieh, C.L.; Abiona, O.; Graham, B.S.; McLellan, J.S. Cryo-EM structure of
the 2019-nCoV spike in the prefusion conformation. Science 2020, 367, 1260–1263. [CrossRef] [PubMed]
55. Xu, C.; Wang, Y.; Liu, C.; Zhang, C.; Han, W.; Hong, X.; Wang, Y.; Hong, Q.; Wang, S.; Zhao, Q.; et al. Conformational dynamics of
SARS-CoV-2 trimeric spike glycoprotein in complex with receptor ACE2 revealed by cryo-EM. Sci. Adv. 2021, 7, eabe5575. [CrossRef]
56. Xia, S.; Yan, L.; Xu, W.; Agrawal, A.S.; Algaissi, A.; Tseng, C.-T.K.; Wang, Q.; Du, L.; Tan, W.; Wilson, I.A.; et al. A pan-coronavirus
fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci. Adv. 2019, 5, eaav4580. [CrossRef] [PubMed]
57. Jin, Z.; Du, X.; Xu, Y.; Deng, Y.; Liu, M.; Zhao, Y.; Zhang, B.; Li, X.; Zhang, L.; Peng, C.; et al. Structure of Mpro from SARS-CoV-2
and discovery of its inhibitors. Nature 2020, 582, 289–293. [CrossRef]
58. Pluskota-Karwatka, D.; Hoffmann, M.; Barciszewski, J. Reducing SARS-CoV-2 pathological protein activity with small molecules.
J. Pharm. Anal. 2021, 11, 383–397. [CrossRef] [PubMed]
59. Shin, D.; Mukherjee, R.; Grewe, D.; Bojkova, D.; Baek, K.; Bhattacharya, A.; Schulz, L.; Widera, M.; Mehdipour, A.R.; Tascher, G.; et al.
Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature 2020, 587, 657–662. [CrossRef]
60. Osipiuk, J.; Azizi, S.-A.; Dvorkin, S.; Endres, M.; Jedrzejczak, R.; Jones, K.A.; Kang, S.; Kathayat, R.S.; Kim, Y.; Lisnyak, V.G.; et al. Structure
of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. Nat. Commun. 2021, 12, 743. [CrossRef]
61. Heustess, A.M.; Allard, M.A.; Thompson, D.K.; Fasinu, P.S. Clinical management of COVID-19: A review of pharmacological
treatment options. Pharmaceuticals 2021, 14, 520. [CrossRef]
62. Zhou, Y.; Hou, Y.; Shen, J.; Huang, Y.; Martin, W.; Cheng, F. Network-based drug repurposing for novel coronavirus 2019-
nCoV/SARS-CoV-2. Cell Discov. 2020, 6, 14. [CrossRef]
63. Gordon, D.E.; Jang, G.M.; Bouhaddou, M.; Xu, J.; Obernier, K.; White, K.M.; O’Meara, M.J.; Rezelj, V.V.; Guo, J.Z.; Swaney, D.L.; et al. A
SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 2020, 583, 459–468. [CrossRef]
64. Mirabelli, C.; Wotring, J.W.; Zhang, C.J.; McCarty, S.M.; Fursmidt, R.; Pretto, C.D.; Qiao, Y.; Zhang, Y.; Frum, T.;
Kadambi, N.S.; et al. Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for
COVID-19. Proc. Natl. Acad. Sci. USA 2021, 118, e2105815118. [CrossRef] [PubMed]
65. Fuzimoto, A.D.; Isidoro, C. The antiviral and coronavirus-host protein pathways inhibiting properties of herbs and natural
compounds—Additional weapons in the fight against the COVID-19 pandemic? J. Tradit. Complement. Med. 2020, 10, 405–419.
[CrossRef] [PubMed]
66. Sayed, A.M.; Khattab, A.R.; AboulMagd, A.M.; Hassan, H.M.; Rateb, M.E.; Zaid, H.; Abdelmohsen, U.R. Nature as a treasure
trove of potential anti-SARS-CoV drug leads: A structural/mechanistic rationale. RSC Adv. 2020, 10, 19790–19802. [CrossRef]
67. Yahfoufi, N.; Alsadi, N.; Jambi, M.; Matar, C. The immunomodulatory and anti-inflammatory role of polyphenols. Nutrients 2018,
10, 1618. [CrossRef] [PubMed]
68. Ghosh, R.; Chakraborty, A.; Biswas, A.; Chowdhuri, S. Evaluation of green tea polyphenols as novel corona virus (SARS-CoV-2)
main protease (Mpro) inhibitors—An in silico docking and molecular dynamics simulation study. J. Biomol. Struct. Dyn. 2021, 39,
4362–4374. [CrossRef]
69. Dalan, R. Is DPP4 inhibition a comrade or adversary in COVID-19 infection. Diabetes Res. Clin. Pract. 2020, 164, 108216. [CrossRef]
70. Singh, R.; Gautam, A.; Chandel, S.; Ghosh, A.; Dey, D.; Roy, S.; Ravichandiran, V.; Ghosh, D. Protease inhibitory effect of natural
polyphenolic compounds on SARS-CoV-2: An In silico Study. Molecules 2020, 25, 4604. [CrossRef]
71. Vijayakumar, B.G.; Ramesh, D.; Joji, A.; Jayachandra prakasan, J.; Kannan, T. In silico pharmacokinetic and molecular docking
studies of natural flavonoids and synthetic indole chalcones against essential proteins of SARS-CoV-2. Eur. J. Pharmacol. 2020,
886, 173448. [CrossRef]
72. Wu, W.; Li, R.; Li, X.; He, J.; Jiang, S.; Liu, S.; Yang, J. Quercetin as an antiviral agent inhibits influenza A Virus (IAV) entry. Viruses
2016, 8, 6. [CrossRef]
73. Zandi, K.; Teoh, B.-T.; Sam, S.-S.; Wong, P.-F.; Mustafa, M.R.; AbuBakar, S. Antiviral activity of four types of bioflavonoid against
dengue virus type-2. Virol. J. 2011, 8, 560. [CrossRef]
74. Chen, L.; Li, J.; Luo, C.; Liu, H.; Xu, W.; Chen, G.; Liew, O.W.; Zhu, W.; Puah, C.M.; Shen, X.; et al. Binding interaction of
quercetin-3-β-galactoside and its synthetic derivatives with SARS-CoV 3CLpro: Structure–activity relationship studies reveal
salient pharmacophore features. Bioorg. Med. Chem. 2006, 14, 8295–8306. [CrossRef] [PubMed]
75. Abian, O.; Ortega-Alarcon, D.; Jimenez-Alesanco, A.; Ceballos-Laita, L.; Vega, S.; Reyburn, H.T.; Rizzuti, B.; Velazquez-Campoy,
A. Structural stability of SARS-CoV-2 3CLpro and identification of quercetin as an inhibitor by experimental screening. Int. J. Biol.
Macromol. 2020, 164, 1693–1703. [CrossRef]
76. Nguyen, T.T.H.; Woo, H.J.; Kang, H.K.; Nguyen, V.D.; Kim, Y.M.; Kim, D.W.; Ahn, S.A.; Xia, Y.; Kim, D. Flavonoid-mediated inhibition
of SARS coronavirus 3C-like protease expressed in Pichia pastoris. Biotechnol. Lett. 2012, 34, 831–838. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2021, 22, 12385 26 of 29
77. Kuba, K.; Imai, Y.; Rao, S.; Gao, H.; Guo, F.; Guan, B.; Huan, Y.; Yang, P.; Zhang, Y.; Deng, W.; et al. A crucial role of angiotensin
converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 2005, 11, 875–879. [CrossRef] [PubMed]
78. Liu, X.; Raghuvanshi, R.; Ceylan, F.D.; Bolling, B.W. Quercetin and its metabolites inhibit recombinant human angiotensin-
converting enzyme 2 (ACE2) activity. J. Agric. Food Chem. 2020, 68, 13982–13989. [CrossRef]
79. Jo, S.; Kim, S.; Shin, D.H.; Kim, M.-S. Inhibition of SARS-CoV 3CL protease by flavonoids. J. Enzym. Inhib. Med. Chem. 2020, 35,
145–151. [CrossRef]
80. Jo, S.; Kim, S.; Kim, D.Y.; Kim, M.-S.; Shin, D.H. Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro. J. Enzym. Inhib.
Med. Chem. 2020, 35, 1539–1544. [CrossRef]
81. Wang, S.-C.; Chen, Y.; Wang, Y.-C.; Wang, W.-J.; Yang, C.-S.; Tsai, C.-L.; Hou, M.-H.; Chen, H.-F.; Shen, Y.-C.; Hung, M.-C. Tannic
acid suppresses SARS-CoV-2 as a dual inhibitor of the viral main protease and the cellular TMPRSS2 protease. Am. J. Cancer Res.
2020, 10, 4538–4546. [PubMed]
82. Wen, C.C.; Kuo, Y.H.; Jan, J.T.; Liang, P.H.; Wang, S.Y.; Liu, H.G.; Lee, C.K.; Chang, S.T.; Kuo, C.J.; Lee, S.S.; et al. Specific plant
terpenoids and lignoids possess potent antiviral activities against severe acute respiratory syndrome coronavirus. J. Med. Chem.
2007, 50, 4087–4095. [CrossRef] [PubMed]
83. Guijarro-Real, C.; Plazas, M.; Rodríguez-Burruezo, A.; Prohens, J.; Fita, A. Potential in vitro inhibition of selected plant extracts
against SARS-CoV-2 chymotripsin-like protease (3CLPro) activity. Foods 2021, 10, 1503. [CrossRef]
84. Delre, P.; Caporuscio, F.; Saviano, M.; Mangiatordi, G.F. Repurposing known drugs as covalent and non-covalent inhibitors of the
SARS-CoV-2 papain-like protease. Front. Chem. 2020, 8, 594009. [CrossRef]
85. Dourado, D.; Freire, D.T.; Pereira, D.T.; Amaral-Machado, L.; Alencar, É.N.; de Barros, A.L.B.; Egito, E.S.T. Will curcumin nanosystems
be the next promising antiviral alternatives in COVID-19 treatment trials? Biomed. Pharmacother. 2021, 139, 111578. [CrossRef]
86. Park, J.Y.; Kim, J.H.; Kwon, J.M.; Kwon, H.J.; Jeong, H.J.; Kim, Y.M.; Kim, D.; Lee, W.S.; Ryu, Y.B. Dieckol, a SARS-CoV 3CLpro
inhibitor, isolated from the edible brown algae Ecklonia cava. Bioorganic Med. Chem. 2013, 21, 3730–3737. [CrossRef] [PubMed]
87. Nguyen, T.T.H.; Jung, J.H.; Kim, M.K.; Lim, S.; Choi, J.M.; Chung, B.; Kim, D.W.; Kim, D. The inhibitory effects of plant derivate
polyphenols on the main protease of SARS coronavirus 2 and their structure–activity relationship. Molecules 2021, 26, 1924. [CrossRef]
88. Jang, M.; Park, Y.I.; Cha, Y.E.; Park, R.; Namkoong, S.; Lee, J.I.; Park, J. Tea polyphenols EGCG and theaflavin inhibit the activity
of SARS-CoV-2 3CL-protease in vitro. Evid.-Based Complement. Altern. Med. 2020, 2020, 5630838. [CrossRef]
89. Xiao, T.; Cui, M.; Zheng, C.; Wang, M.; Sun, R.; Gao, D.; Bao, J.; Ren, S.; Yang, B.; Lin, J.; et al. Myricetin inhibits SARS-CoV-2 viral
replication by targeting Mpro and ameliorates pulmonary inflammation. Front. Pharmacol. 2021, 12, 669642. [CrossRef]
90. Yu, M.-S.; Lee, J.; Lee, J.M.; Kim, Y.; Chin, Y.-W.; Jee, J.-G.; Keum, Y.-S.; Jeong, Y.-J. Identification of myricetin and scutellarein as
novel chemical inhibitors of the SARS coronavirus helicase, nsP13. Bioorg. Med. Chem. Lett. 2012, 22, 4049–4054. [CrossRef]
91. Park, J.Y.; Ko, J.A.; Kim, D.W.; Kim, Y.M.; Kwon, H.J.; Jeong, H.J.; Kim, C.Y.; Park, K.H.; Lee, W.S.; Ryu, Y.B. Chalcones isolated
from Angelica keiskei inhibit cysteine proteases of SARS-CoV. J. Enzym. Inhib. Med. Chem. 2016, 31, 23–30. [CrossRef]
92. Park, J.; Yuk, H.J.; Ryu, H.W.; Lim, S.H.; Kim, K.S.; Park, K.H.; Ryu, Y.B.; Lee, W.S. Evaluation of polyphenols from Broussonetia
papyrifera as coronavirus protease inhibitors. J. Enzym. Inhib. Med. Chem. 2017, 32, 504–512. [CrossRef] [PubMed]
93. Kim, D.W.; Seo, K.H.; Curtis-Long, M.J.; Oh, K.Y.; Oh, J.-W.; Cho, J.K.; Lee, K.H.; Park, K.H. Phenolic phytochemical displaying
SARS-CoV papain-like protease inhibition from the seeds of Psoralea corylifolia. J. Enzym. Inhib. Med. Chem. 2014, 29, 59–63. [CrossRef]
94. Ibrahim, T.M.; Ismail, M.I.; Bauer, M.R.; Bekhit, A.A.; Boeckler, F.M. Supporting SARS-CoV-2 papain-like protease drug discovery:
In silico methods and benchmarking. Front. Chem. 2020, 8, 592289. [CrossRef] [PubMed]
95. Huynh, T.; Cornell, W.; Luan, B. In silico Exploration of inhibitors for SARS-CoV-2′s papain-like protease. Front. Chem. 2021, 8,
624163. [CrossRef] [PubMed]
96. Goc, A.; Sumera, W.; Rath, M.; Niedzwiecki, A. Phenolic compounds disrupt spike-mediated receptor-binding and entry of
SARS-CoV-2 pseudo-virions. PLoS ONE 2021, 16, e0253489. [CrossRef]
97. Tito, A.; Colantuono, A.; Pirone, L.; Pedone, E.; Intartaglia, D.; Giamundo, G.; Conte, I.; Vitaglione, P.; Apone, F. Pomegranate peel
extract as an inhibitor of SARS-CoV-2 spike binding to human ACE2 receptor (in vitro): A promising source of novel antiviral
drugs. Front. Chem. 2021, 9, 638187. [CrossRef] [PubMed]
98. Ho, T.Y.; Wu, S.L.; Chen, J.C.; Li, C.C.; Hsiang, C.Y. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting
enzyme 2 interaction. Antivir. Res. 2007, 74, 92–101. [CrossRef]
99. Dellafiora, L.; Dorne, J.L.C.M.; Galaverna, G.; Dall’Asta, C. Preventing the interaction between coronaviruses spike protein and
angiotensin I converting enzyme 2: An in silico mechanistic case study on emodin as a potential model compound. Appl. Sci.
2020, 10, 6358. [CrossRef]
100. Gianchecchi, E.; Fierabracci, A. Insights on the effects of resveratrol and some of its derivatives in cancer and autoimmunity: A
molecule with a dual activity. Antioxidants 2020, 9, 91. [CrossRef] [PubMed]
101. Banez, M.J.; Geluz, M.I.; Chandra, A.; Hamdan, T.; Biswas, O.S.; Bryan, N.S.; Von Schwarz, E.R. A systemic review on
the antioxidant and anti-inflammatory effects of resveratrol, curcumin, and dietary nitric oxide supplementation on human
cardiovascular health. Nutr. Res. 2020, 78, 11–26. [CrossRef]
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resveratrol in prevention and control of cardiovascular disorders and cardiovascular complications related to COVID-19 disease:
Mode of action and approaches explored to increase its bioavailability. Molecules 2021, 26, 2834. [CrossRef] [PubMed]
103. Ramdani, L.H.; Bachari, K. Potential therapeutic effects of Resveratrol against SARS-CoV-2. Acta Virol. 2020, 64, 276–280. [CrossRef]
Int. J. Mol. Sci. 2021, 22, 12385 27 of 29
104. Palamara, A.T.; Nencioni, L.; Aquilano, K.; De Chiara, G.; Hernandez, L.; Cozzolino, F.; Ciriolo, M.R.; Garaci, E. Inhibition of
influenza A virus replication by resveratrol. J. Infect. Dis. 2005, 191, 1719–1729. [CrossRef] [PubMed]
105. Mastromarino, P.; Capobianco, D.; Cannata, F.; Nardis, C.; Mattia, E.; De Leo, A.; Restignoli, R.; Francioso, A.; Mosca, L.
Resveratrol inhibits rhinovirus replication and expression of inflammatory mediators in nasal epithelia. Antivir. Res. 2015, 123,
15–21. [CrossRef]
106. Mohd, A.; Zainal, N.; Tan, K.K.; AbuBakar, S. Resveratrol affects Zika virus replication in vitro. Sci. Rep. 2019, 9, 14336. [CrossRef] [PubMed]
107. Lin, S.C.; Ho, C.T.; Chuo, W.H.; Li, S.M.; Wang, T.T.; Lin, C.C. Effective inhibition of MERS-CoV infection by resveratrol. Bmc
Infect. Dis. 2017, 17, 144. [CrossRef]
108. Kim, E.N.; Kim, M.Y.; Lim, J.H.; Kim, Y.; Shin, S.J.; Park, C.W.; Kim, Y.S.; Chang, Y.S.; Yoon, H.E.; Choi, B.S. The protective effect
of resveratrol on vascular aging by modulation of the renine-angiotensin system. Atherosclerosis 2018, 270, 123–131. [CrossRef]
109. Cheng, H.; Wang, Y.; Wang, G.Q. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of
COVID-19. J. Med. Virol. 2020, 92, 726–730. [CrossRef]
110. Wahedi, H.M.; Ahmad, S.; Abbasi, S.W. Stilbene-based natural compounds as promising drug candidates against COVID-19. J.
Biomol. Struct. Dyn. 2021, 39, 3225–3234. [CrossRef]
111. Yang, M.; Wei, J.; Huang, T.; Lei, L.; Shen, C.; Lai, J.; Yang, M.; Liu, L.; Yang, Y.; Liu, G.; et al. Resveratrol inhibits the replication of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in cultured Vero cells. Phyther. Res. 2021, 35, 1127–1129. [CrossRef]
112. Pasquereau, S.; Nehme, Z.; Haidar Ahmad, S.; Daouad, F.; Van Assche, J.; Wallet, C.; Schwartz, C.; Rohr, O.; Morot-Bizot, S.;
Herbein, G. Resveratrol inhibits HCoV-229E and SARS-CoV-2 coronavirus replication in vitro. Viruses 2021, 13, 354. [CrossRef]
113. ter Ellen, B.M.; Dinesh Kumar, N.; Bouma, E.M.; Troost, B.; van de Pol, D.P.I.; van der Ende-Metselaar, H.H.; Apperloo, L.; van
Gosliga, D.; van den Berge, M.; Nawijn, M.C.; et al. Resveratrol and pterostilbene inhibit SARS-CoV-2 replication in air–liquid
interface cultured human primary bronchial epithelial cells. Viruses 2021, 13, 1335. [CrossRef] [PubMed]
114. Nagao, K.; Jinnouchi, T.; Kai, S.; Yanagita, T. Pterostilbene, a dimethylated analog of resveratrol, promotes energy metabolism in
obese rats. J. Nutr. Biochem. 2017, 43, 151–155. [CrossRef]
115. Tsvetkov, V.; Varizhuk, A.; Kozlovskaya, L.; Shtro, A.; Lebedeva, O.; Komissarov, A.; Vedekhina, T.; Manuvera, V.; Zubkova, O.;
Eremeev, A.; et al. EGCG as an anti-SARS-CoV-2 agent: Preventive versus therapeutic potential against original and mutant virus.
Biochimie 2021, 191, 27–32. [CrossRef]
116. Abd El-Aziz, T.M.; Stockand, J.D. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-
CoV-2)—An update on the status. Infect. Genet. Evol. 2020, 83, 104327. [CrossRef]
117. Bettuzzi, S.; Gabba, L.; Cataldo, S. Efficacy of a polyphenolic, standardized green tea extract for the treatment of COVID-19
syndrome: A proof-of-principle study. COVID 2021, 1, 2. [CrossRef]
118. Bocchi, L.; Savi, M.; Naponelli, V.; Vilella, R.; Sgarbi, G.; Baracca, A.; Solaini, G.; Bettuzzi, S.; Rizzi, F.; Stilli, D. Long-term
oral administration of theaphenon-e improves cardiomyocyte mechanics and calcium dynamics by affecting phospholamban
phosphorylation and ATP production. Cell. Physiol. Biochem. 2018, 47, 1230–1243. [CrossRef] [PubMed]
119. Brausi, M.; Rizzi, F.; Bettuzzi, S. Chemoprevention of human prostate cancer by green tea catechins: Two years later. a follow-up
update. Eur. Urol. 2008, 54, 472–473. [CrossRef]
120. Hara, Y. Tea catechins and their applications as supplements and pharmaceutics. Pharmacol. Res. 2011, 64, 100–104. [CrossRef] [PubMed]
121. Tatti, S.; Swinehart, J.M.; Thielert, C.; Tawfik, H.; Mescheder, A.; Beutner, K.R. Sinecatechins, a Defined Green Tea Extract, in the
Treatment of External Anogenital Warts. Obstet. Gynecol. 2008, 111, 1371–1379. [CrossRef]
122. Younes, M.; Aggett, P.; Aguilar, F.; Crebelli, R.; Dusemund, B.; Filipič, M.; Frutos, M.J.; Galtier, P.; Gott, D.; Gundert-Remy, U.; et al.
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